Details of the Drug

General Information of Drug (ID: DMOBIKY)

Drug Name

Bexarotene

Synonyms

Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous T-cell lymphoma	2B01	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[2]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[2]
Schizoaffective disorder	6A21	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Affected Organisms

Humans and other mammals

ATC Code

L01XF03: Bexarotene

L01XF: Retinoids for cancer treatment

L01X: OTHER ANTINEOPLASTIC AGENTS

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

348.5

Logarithm of the Partition Coefficient (xlogp)

7.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination: 0.01% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 7 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 28.6961 micromolar/kg/day [5]

Chemical Identifiers

Formula: C24H28O2
IUPAC Name: 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
Canonical SMILES: CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
InChI: InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
InChIKey: NAVMQTYZDKMPEU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 82146
ChEBI ID: CHEBI:50859
CAS Number: 153559-49-0
UNII: A61RXM4375
DrugBank ID: DB00307
TTD ID: D0N0RU
INTEDE ID: DR0208
ACDINA ID: D00068

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Retinoic acid receptor RXR-alpha (RXRA)	TT6PEUO	RXRA_HUMAN	Modulator	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[8]
Adipogenesis regulatory factor (ADIRF)	OTTJP8D4	ADIRF_HUMAN	Gene/Protein Processing	[9]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[9]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[9]
Angiomotin-like protein 2 (AMOTL2)	OTRCTKV9	AMOL2_HUMAN	Gene/Protein Processing	[9]
Apolipoprotein A-II (APOA2)	OTQ3HGTC	APOA2_HUMAN	Gene/Protein Processing	[10]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[9]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[11]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 (BNIP2)	OTVZD4H6	BNIP2_HUMAN	Gene/Protein Processing	[9]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Gene/Protein Processing	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1	5.1371	17.4867	-2.5486	25.8913
EW-13	GDSC1	0.2558	17.4546	-6.6247	46.082
ES4	GDSC1	1.6157	11.4155	-2.4106	36.5645
NOS-1 [Human HNSCC]	GDSC1	2.5527	8.8909	-0.326	25.3587
NY	GDSC1	2.9322	4.8646	2.0106	8.0506
ES8	GDSC1	3.112	4.6064	2.2881	5.2221
ES6	GDSC1	3.2735	7.0932	1.1766	13.2343
ES7	GDSC1	3.3749	9.9041	-0.1448	21.3233
ES1	GDSC1	3.8295	7.8605	1.2216	11.107
EW-18	GDSC1	4.4079	9.2193	0.9711	11.1943
EW-1	GDSC1	4.5633	7.1632	2.0317	3.4934
CHSA8926	GDSC1	4.6555	6.39	2.4058	1.1429
EW-3	GDSC1	4.6761	7.1238	2.1105	2.7906
TC-71	GDSC1	4.7368	6.5272	2.3882	1.1421
EW-24	GDSC1	4.7506	6.4667	2.4182	0.9864
H-EMC-SS	GDSC1	4.8087	9.6713	1.0245	9.7917
CHSA0108	GDSC1	4.9219	7.3767	2.1298	2.2978
EW-16	GDSC1	5.071	16.7436	-2.2315	25.0456
HuO9	GDSC1	5.0759	7.1482	2.2954	1.2375
SK-PN-DW	GDSC1	5.0895	8.0036	1.9501	3.1095
EW-7	GDSC1	5.1162	10.6627	0.7562	10.7712
HuO-3N1	GDSC1	5.1971	32.8013	-10.1116	38.0076
SK-ES-1	GDSC1; CTRP2	5.622	7.8018	4.7929	6.1368
A-673	GDSC1; CTRP2	5.7704	6.6438	5.4941	2.9025
EW-11	GDSC1	5.8655	12.4573	0.3927	11.2178
CHSA0011	GDSC1	5.8693	7.8499	2.3567	0.4577
CAL-72	GDSC1	6.0063	17.6495	-1.9957	21.9338
ES5	GDSC1	6.0737	8.5713	2.1747	0.9198
SaOS-2	GDSC1; CTRP2	6.291	7.9889	5.2692	2.8122
Hs 822.T	CTRP2	7.2091	8.1478	5.7345	0.1805
TC71	CTRP2	7.3399	9.2675	5.3415	1.2022
U2OS	GDSC1; CTRP2	7.4788	9.2601	4.4626	0.2804
SK-N-MC	CTRP2	7.5244	8.4429	5.7486	0.0796
SW1353	CTRP2	8.1098	9.3258	5.6542	0.0873
HOS	GDSC1; CTRP2	8.3575	9.634	5.6363	0.0715
G-292 clone A141B1	GDSC1; CTRP2	8.5813	10.1037	5.5553	0.1171
MHH-ES-1	GDSC1; CTRP2	8.7312	10.5244	5.4637	0.1984
SJSA-1	GDSC1; CTRP2	8.901	19.6106	1.4693	13.5468
Hs 888.T	CTRP2	9.1273	17.8187	2.4858	9.6789
CAL-78	GDSC1; CTRP2	10.6601	20.3706	2.2648	8.5323
MG-63	GDSC1; CTRP2	10.9852	25.917	-0.137	15.5094
-----------


⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 210 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	9.4821	21.8745	0.7789	14.9117
MEC1	CTRP2	9.593	25.1489	-0.7362	19.0285
JM1	GDSC1	4.9083	9.1554	1.33	7.5092
MV4-11	GDSC1; CTRP2	-2.1446	6.8692	-3.1306	53.2924
SIG-M5	GDSC1; CTRP2	-1.9411	2.0383	-1.9846	53.0993
Karpas-231	GDSC1	-0.8185	30.0989	-13.8499	49.6798
HH [Human lymphoma]	GDSC1; CTRP2	0.0155	20.1093	-6.4797	46.1838
NCI-H929	CTRP2	1.1079	10.4206	-0.9474	38.0488
ALL-PO	GDSC1	1.5689	8.3676	-0.9532	32.4066
ATN-1	GDSC1	1.6749	9.0536	-1.1914	32.7999
HuT 78	CTRP2	1.7216	12.2515	-1.1258	36.412
OCI-AML-3	GDSC1; CTRP2	2.0657	9.9406	0.2513	32.2322
EoL-1	GDSC1	2.7278	8.9237	-0.1917	23.9705
YT	GDSC1	2.9578	4.4303	2.2494	6.0743
Jiyoye	GDSC1	2.9582	4.5669	2.1815	6.6082
SU-DHL-16	GDSC1	3.141	9.8474	-0.3069	23.0131
EM-2	GDSC1; CTRP2	3.1629	9.101	1.747	24.3229
CCRF-CEM	GDSC1	3.2434	9.3988	0.0012	20.9845
KOPN-8	GDSC1	3.2632	5.7175	1.8539	8.1214
Farage	GDSC1	3.3078	4.7935	2.345	4.1523
ML-2	GDSC1	3.3664	5.8286	1.8782	7.5975
SU-DHL-5	GDSC1	3.4099	4.926	2.3536	3.7912
MHH-PREB-1	GDSC1	3.4101	5.5423	2.0524	6.1113
KMOE-2	GDSC1	3.4508	5.136	2.2804	4.2357
BC-1	GDSC1	3.4736	5.2957	2.2189	4.6413
MEG-01	GDSC1	3.5459	8.0591	0.9098	14.2136
BC-3	GDSC1	3.5477	7.838	1.021	13.4291
BE-13	GDSC1	3.7253	6.4371	1.842	6.8034
DB	GDSC1	3.7686	6.4142	1.8833	6.3721
TK [Human B-cell lymphoma]	GDSC1	3.84	5.1941	2.4986	1.7553
KY821	GDSC1	3.8451	5.5663	2.3341	2.8654
DoHH2	GDSC1	3.8663	6.1476	2.0764	4.6769
MOLT-4	GDSC1	3.8714	7.407	1.4737	9.1433
JSC-1	GDSC1	3.9084	5.7225	2.3007	2.9643
SKM-1	CTRP2	3.9627	11.3088	1.5253	22.9746
WIL2 NS	GDSC1	3.9919	7.9841	1.2784	10.2183
Ramos.2G6.4C10	GDSC1	4.0027	5.339	2.5226	1.337
ME1	GDSC1	4.007	8.2242	1.1722	10.9331
CTV-1	GDSC1	4.0884	6.7657	1.9285	5.2171
HC-1	GDSC1	4.1025	7.9085	1.3928	9.083
KMS-12-BM	GDSC1; CTRP2	4.1167	5.7472	4.0137	13.1977
LC4-1	GDSC1	4.1911	20.2772	-4.6671	33.3458
P32/ISH	GDSC1	4.2477	12.4564	-0.7329	21.4468
SU-DHL-6	GDSC1; CTRP2	4.3055	10.5537	2.216	19.6187
EB2	GDSC1	4.3325	7.4918	1.7437	5.9669
BL-41	GDSC1	4.3642	6.4706	2.2264	2.5867
Sc-1	GDSC1	4.3858	6.2046	2.3521	1.7778
RC-K8	GDSC1	4.3982	6.1907	2.3642	1.6892
IM-9	GDSC1	4.4982	6.0981	2.4502	1.0945
ARH-77	GDSC1	4.5221	8.0623	1.5969	6.5605
CESS	GDSC1	4.5299	10.2086	0.5774	13.427
PL-21	GDSC1	4.5578	15.6875	-2.0969	25.9631
SUP-T11	CTRP2	4.6765	6.2059	4.5045	9.7214
NKM-1	GDSC1	4.6959	16.529	-2.4084	26.5986
SCC-3	GDSC1	4.7207	6.0864	2.55	0.4729
P30/OHK	GDSC1	4.7343	6.3423	2.4593	0.8176
Pfeiffer	CTRP2	4.7604	23.4526	-3.7516	33.4281
SK-MM-2	GDSC1	4.7681	11.2659	0.2318	14.8649
MOLT-13	CTRP2	4.8248	11.8652	1.4493	16.3428
AML-193	CTRP2	4.8405	5.3999	4.836	8.0354
HAL-01	GDSC1	4.8947	7.4739	2.075	2.6607
NK-92MI	GDSC1	4.9075	6.4265	2.4993	0.5307
BALL-1	GDSC1	4.9277	6.6855	2.4103	0.8604
U-698-M	GDSC1	4.9279	7.774	1.9636	3.2883
Loucy	GDSC1	4.9383	23.0759	-5.4719	33.0448
GA-10	CTRP2	4.9813	15.3678	0.4696	23.963
VAL	GDSC1	5.002	7.3572	2.1773	1.9234
QIMR-WIL	GDSC1	5.0135	13.1415	-0.5065	18.1715
RPMI-8866	GDSC1	5.0315	7.2058	2.2525	1.4933
A4/Fukuda	GDSC1; CTRP2	5.0656	15.9696	0.2442	24.4373
DG-75	GDSC1	5.0843	7.2693	2.2514	1.441
TUR	GDSC1	5.0887	14.7782	-1.252	21.3569
Daudi	GDSC1; CTRP2	5.1211	7.9892	4.2255	9.6361
VL51	GDSC1	5.1353	7.0839	2.3463	0.9553
SEM	CTRP2	5.1435	6.3463	4.965	6.6448
H9	GDSC1	5.1469	7.0674	2.3575	0.8988
MY-M12	GDSC1	5.158	11.5782	0.3486	13.1533
TALL-1 [Human adult T-ALL]	CTRP2	5.1911	6.8141	4.8302	7.0323
KG-1	GDSC1	5.2424	6.8562	2.4738	0.4235
MLMA	GDSC1	5.2498	6.9267	2.4512	0.4878
HD-MY-Z	CTRP2	5.2602	7.0502	4.7979	6.9799
DEL	GDSC1; CTRP2	5.269	6.3163	5.111	5.7358
WSU-NHL	GDSC1	5.3555	6.8182	2.529	0.2384
MN-60	GDSC1	5.3758	7.7848	2.179	1.4849
MM1.S	CTRP2	5.4149	7.9517	3.1175	2.4337
GR-ST	GDSC1	5.426	8.4335	1.9396	2.6767
JVM-2	GDSC1; CTRP2	5.443	9.6886	3.6997	11.074
CTB-1	GDSC1	5.5545	12.6587	0.0977	13.6069
Mino	CTRP2	5.5564	20.267	-1.4775	27.7453
Hs 445	GDSC1	5.5572	6.9915	2.5411	0.1607
ROS-50	GDSC1	5.5884	7.8408	2.2492	0.9865
JVM-3	GDSC1; CTRP2	5.6502	14.0827	1.0197	16.3093
MHH-CALL-3	CTRP2	5.7375	24.116	-3.2484	30.7933
SET-2	CTRP2	5.7451	6.5934	5.493	2.9686
OCI-AML-2	GDSC1; CTRP2	5.8119	11.4491	2.457	10.1005
MOLM-6	CTRP2	5.8922	16.8797	0.4994	21.938
Mono-Mac-6	GDSC1; CTRP2	5.9539	23.6186	-2.8182	29.6481
JURL-MK1	GDSC1; CTRP2	6.2774	11.3345	3.5909	9.8514
Ku812	GDSC1; CTRP2	6.4305	15.3338	1.7174	16.8586
KHM-1B	CTRP2	6.5875	10.0129	3.6981	3.5158
EHEB	GDSC1; CTRP2	6.6684	12.6863	2.4776	8.5368
HL-60	GDSC1; CTRP2	6.682	21.335	-1.0762	24.6615
NB4	GDSC1; CTRP2	6.7089	9.5694	3.9723	2.2826
MOLM-13	GDSC1; CTRP2	6.7509	21.3682	-1.037	24.4405
ST486	GDSC1; CTRP2	6.7529	13.7545	2.7627	12.3336
Karpas-45	GDSC1	6.9436	16.8178	-0.9638	15.7256
MC116	GDSC1; CTRP2	6.9524	8.2109	5.5915	0.7112
MOLT-3	CTRP2	7.0288	8.1331	5.6617	0.4419
SU-DHL-10	CTRP2	7.0622	8.1627	5.6655	0.4109
NOMO-1	GDSC1; CTRP2	7.0818	18.9174	0.4507	19.8055
P3HR-1	CTRP2	7.0917	9.2357	5.2141	1.9116
GDM-1	GDSC1; CTRP2	7.1627	13.5421	2.4049	8.0736
Hs 611.T	CTRP2	7.2298	13.9757	3.0181	10.5034
EJM	GDSC1; CTRP2	7.3417	12.4395	3.8529	6.975
WSU-DLCL2	GDSC1; CTRP2	7.3822	8.6688	5.6094	0.3783
SUP-M2	GDSC1; CTRP2	7.3974	18.0948	1.1063	17.1813
Karpas-422	GDSC1; CTRP2	7.4034	12.3675	3.9313	6.5658
AMO1	GDSC1; CTRP2	7.471	8.7824	5.6039	0.3486
SU-DHL-1	GDSC1; CTRP2	7.5403	8.661	5.6775	0.1763
OPM-2	GDSC1; CTRP2	7.5553	9.3	5.4369	0.7355
KMS-26	CTRP2	7.5573	8.491	5.7439	0.0794
SU-DHL-4	GDSC1; CTRP2	7.5573	12.4172	4.0136	6.0114
MOLP-8	GDSC1; CTRP2	7.6678	9.3787	5.4577	0.6078
RPMI-6666	GDSC1; CTRP2	7.6801	24.8531	-2.034	25.0798
PL21	CTRP2	7.6914	20.2376	0.2693	19.2723
KMS-27	CTRP2	7.7056	8.9633	5.6321	0.2039
KE-97	CTRP2	7.7175	9.244	5.5323	0.3987
MOLM-16	CTRP2	7.7226	9.9202	5.2619	1.1409
A3/Kawakami	GDSC1; CTRP2	7.7695	13.0754	3.8419	6.3944
Reh	GDSC1; CTRP2	7.7742	9.1835	5.5786	0.2787
Granta-519	GDSC1; CTRP2	7.7762	11.7858	4.4566	3.9769
Raji	GDSC1; CTRP2	7.783	9.3459	5.5211	0.3944
HDLM-2	GDSC1; CTRP2	7.8474	22.862	-0.9131	22.2141
KYO-1	CTRP2	7.9189	14.1324	3.4359	7.7832
P12-Ichikawa	GDSC1; CTRP2	7.9491	9.207	5.6374	0.1345
OCI-AML-5	GDSC1; CTRP2	7.9581	9.0172	5.7058	0.06
HEL	GDSC1; CTRP2	8.0135	9.1895	5.6667	0.0889
Kasumi-2	CTRP2	8.0423	9.4437	5.5885	0.1814
KMS-20	CTRP2	8.0483	9.518	5.5642	0.2174
HT	GDSC1; CTRP2	8.0554	9.354	5.625	0.1289
Jurkat	CTRP2	8.0705	9.7299	5.4955	0.3328
U266B1	GDSC1; CTRP2	8.0897	9.8199	5.4698	0.3768
KO52	CTRP2	8.0955	20.1367	0.626	17.5219
Mono-Mac-1	CTRP2	8.1094	22.3968	-0.4811	20.6659
RPMI-8226	GDSC1; CTRP2	8.1219	21.1787	0.1312	18.9511
L-1236	GDSC1; CTRP2	8.1233	11.0706	4.9793	1.7202
THP-1	GDSC1; CTRP2	8.1451	9.5328	5.5954	0.1485
MHH-CALL-4	CTRP2	8.1479	9.9801	5.4336	0.4289
U-937	CTRP2	8.1524	9.5243	5.601	0.1398
M-07e	CTRP2	8.1774	9.505	5.6168	0.1163
P31/FUJ	GDSC1; CTRP2	8.1851	9.2781	5.6962	0.0445
RPMI-8402	GDSC1; CTRP2	8.2125	9.9287	5.479	0.3145
KE-37	GDSC1; CTRP2	8.2203	9.3886	5.6714	0.0587
SUP-B15	GDSC1; CTRP2	8.2271	9.8871	5.5	0.2725
BV-173	GDSC1; CTRP2	8.2507	13.3708	4.016	5.0801
L-540	GDSC1; CTRP2	8.2546	9.8273	5.5322	0.2126
Kasumi-1	CTRP2	8.2556	10.2582	5.3732	0.5143
SR	GDSC1; CTRP2	8.2599	9.9485	5.4905	0.2789
MOLT-16	GDSC1; CTRP2	8.2738	9.5844	5.6239	0.0935
ALL-SIL	GDSC1; CTRP2	8.2799	9.8804	5.5228	0.2204
SUP-HD1	GDSC1; CTRP2	8.2993	18.0009	1.8253	13.2435
L-428	GDSC1; CTRP2	8.3123	9.886	5.533	0.197
Ci-1	CTRP2	8.3255	20.2943	0.7196	16.8589
JJN-3	GDSC1; CTRP2	8.3288	9.8289	5.5593	0.1574
HPB-ALL	CTRP2	8.3306	9.7201	5.5976	0.1119
KMS-11	CTRP2	8.3511	10.0455	5.4907	0.2518
CML-T1	CTRP2	8.3522	9.6712	5.6219	0.0847
Ki-JK	CTRP2	8.3887	10.1674	5.4612	0.29
SUP-T1	GDSC1; CTRP2	8.3949	9.9444	5.5431	0.1647
LP-1	GDSC1; CTRP2	8.4184	13.3412	4.1333	4.4355
PF-382	GDSC1; CTRP2	8.4485	10.0041	5.5419	0.1555
RCH-ACV	CTRP2	8.4759	10.4966	5.3748	0.4208
REC-1	CTRP2	8.5441	10.4318	5.4258	0.3037
KM-H2	GDSC1; CTRP2	8.5491	9.9177	5.6071	0.0737
F-36P	CTRP2	8.5529	10.463	5.4179	0.3146
DND-41	GDSC1; CTRP2	8.5627	10.1613	5.5287	0.1498
MOTN-1	CTRP2	8.5855	19.3714	1.3617	14.3839
Peer	CTRP2	8.5956	9.902	5.6282	0.0539
OCI-Ly19	GDSC1; CTRP2	8.5974	10.7741	5.3208	0.4834
KMS-21-BM	CTRP2	8.6179	10.1242	5.5613	0.1057
ME1	CTRP2	8.6956	16.7495	2.7076	9.462
NU-DHL-1	CTRP2	8.7119	10.1671	5.5795	0.0779
Karpas-299	GDSC1; CTRP2	8.7244	10.1455	5.591	0.0678
LAMA-84	GDSC1; CTRP2	8.7381	10.4883	5.4788	0.1774
KMM-1	CTRP2	8.748	10.9898	5.3017	0.4642
NCO2	CTRP2	8.7747	11.0841	5.2775	0.5027
KCL-22	GDSC1; CTRP2	8.8143	10.3514	5.5529	0.088
OCI-Ly10	CTRP2	9.0517	11.0258	5.406	0.2069
CMK	CTRP2	9.1135	18.1609	2.3135	10.316
EB1	CTRP2	9.1682	22.6969	0.1562	17.2308
BL-70	CTRP2	9.3067	22.3037	0.447	16.173
K-562	GDSC1; CTRP2	9.4423	19.0793	2.0948	10.6384
NALM-6	GDSC1; CTRP2	9.5505	18.1086	2.624	8.6284
KMS-18	CTRP2	9.5578	25.2988	-0.8349	19.3325
OCI-Ly3	CTRP2	9.6755	20.435	1.6039	11.9932
NU-DUL-1	GDSC1; CTRP2	9.8106	22.2853	0.8079	14.3554
Namalwa	GDSC1; CTRP2	9.8911	20.7105	1.6162	11.6615
Ri-1	CTRP2	10.1365	24.1211	0.1473	15.8566
MOLP-2	CTRP2	10.3794	29.3615	-2.2285	21.42
RL	GDSC1; CTRP2	10.4383	19.1267	2.7011	7.302
CA46	GDSC1; CTRP2	10.7216	22.0805	1.5085	10.9467
HuNS1	CTRP2	10.7689	28.035	-1.3058	18.7955
697	GDSC1; CTRP2	10.8053	22.2266	1.4933	10.8924
RS4;11	GDSC1; CTRP2	11.2535	22.5642	1.6166	9.9652
Karpas-620	GDSC1; CTRP2	11.4215	24.9956	0.5877	12.9067
SU-DHL-8	GDSC1; CTRP2	11.5068	25.6288	0.3445	13.5035
OCI-M1	GDSC1; CTRP2	11.6714	24.9754	0.7566	12.11
L-363	GDSC1; CTRP2	11.8618	23.9377	1.3556	10.088
JeKo-1	CTRP2	12.7322	27.3887	0.2972	12.2044
HEL 92.1.7	CTRP2	13.4998	30.1583	-0.5107	13.5064
-----------


⏷ Show the Full List of 210 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE8	CTRP2	6.3397	16.3397	1.1407	19.0166
TE15	CTRP2	11.7356	43.3501	-8.104	28.943
T.T	GDSC1	1.851	5.0521	0.9091	21.0206
TE-15	GDSC1	3.5523	6.0965	1.8844	6.9797
TE-6	GDSC1; CTRP2	4.4675	7.1114	3.9485	12.4193
KYSE-270	GDSC1	4.9513	7.0046	2.2961	1.3645
TE-8	GDSC1	5.5317	15.3341	-1.2057	20.0182
TE-5	GDSC1; CTRP2	6.1295	8.0747	5.0992	3.8117
KYSE-70	GDSC1; CTRP2	6.461	10.5975	2.533	3.595
KYSE-410	GDSC1; CTRP2	6.5521	10.0587	4.443	5.8119
TE-10	GDSC1; CTRP2	7.4841	9.225	4.4772	0.2543
TE-4	CTRP2	7.5497	26.2931	-2.8545	26.9401
KYSE-150	GDSC1; CTRP2	7.607	10.9391	4.7443	3.0829
TE-9	GDSC1; CTRP2	7.6313	9.0087	4.6048	0.0716
OE19	GDSC1; CTRP2	7.7092	8.8766	5.6647	0.1509
OE33	GDSC1; CTRP2	7.724	9.4104	5.4705	0.5434
KYSE-30	CTRP2	7.9989	9.3154	5.6177	0.1501
KYSE-510	GDSC1; CTRP2	8.0373	9.8886	5.4217	0.5038
EC-GI-10	GDSC1; CTRP2	8.057	10.2866	5.2735	0.8715
TE-11	GDSC1; CTRP2	8.1568	9.5591	5.5905	0.1525
KYSE-450	GDSC1; CTRP2	8.3352	9.5474	5.6576	0.0574
TE-14	CTRP2	8.3816	10.0719	5.4929	0.2399
OE21	GDSC1; CTRP2	8.4213	17.8356	1.993	12.4635
COLO 680N	GDSC1; CTRP2	8.6272	9.9243	5.6315	0.0492
TE-1	GDSC1; CTRP2	8.8291	10.3056	5.5733	0.0705
KYSE-140	GDSC1; CTRP2	9.0581	11.0689	5.3932	0.2224
KYSE-520	GDSC1; CTRP2	9.1424	11.2132	5.3737	0.2303
KYSE-180	GDSC1; CTRP2	11.1203	21.3167	2.1092	8.5262
-----------


⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	8.0363	10.3581	5.2346	0.995
KP-1N	GDSC1	3.277	4.8428	2.298	4.6106
Panc 10.05	GDSC1	3.5563	13.7599	-1.9237	28.327
SU.86.86	GDSC1; CTRP2	4.6592	6.6915	4.3172	10.4723
KP-4	GDSC1; CTRP2	4.8247	5.9364	4.7411	8.4156
Panc 02.03	GDSC1	5.0443	6.6623	2.467	0.5561
PSN1	GDSC1; CTRP2	5.3539	9.737	3.5952	11.6997
PK-59	CTRP2	5.6394	8.17	3.1484	2.0384
PL4	GDSC1	5.6444	7.1891	2.5046	0.202
HPAC	GDSC1; CTRP2	5.6494	8.6749	2.9277	2.9416
TCC-Pan2	CTRP2	5.8508	7.8159	3.4073	0.8932
Panc 05.04	CTRP2	5.9066	7.6019	3.517	0.5345
MZ-PC-1	GDSC1	6.3468	27.5618	-6.6155	32.0674
PaTu 8988s	CTRP2	6.6408	8.0396	5.4892	1.4025
SNU-410	CTRP2	7.0778	15.5957	2.1003	14.2794
QGP-1	CTRP2	7.1188	8.771	4.4997	0.3298
PaTu 8988t	GDSC1; CTRP2	7.42	8.6778	5.6223	0.3302
KP-2	GDSC1; CTRP2	7.7886	9.2221	5.57	0.2901
DAN-G	GDSC1; CTRP2	7.7984	9.1627	5.5958	0.2384
PaTu 8902	GDSC1; CTRP2	7.8538	9.0324	5.6635	0.1204
Panc 03.27	GDSC1; CTRP2	8.1459	10.5354	5.2146	0.9797
MIA PaCa-2	GDSC1; CTRP2	8.2236	24.4203	-1.3966	22.7641
SUIT-2	GDSC1; CTRP2	8.2427	14.9686	3.2547	8.0268
Hs 766T	GDSC1; CTRP2	8.3564	10.1174	5.4668	0.2903
HuP-T4	GDSC1; CTRP2	8.3581	10.1354	5.4609	0.3
L3.3	CTRP2	8.511	9.6477	5.6836	0.0292
SW1990	GDSC1; CTRP2	8.5197	15.5022	3.1852	7.91
HuP-T3	GDSC1; CTRP2	8.5654	10.1044	5.5494	0.1259
Panc 04.03	GDSC1; CTRP2	8.5966	11.9504	4.8493	1.7506
AsPC-1	GDSC1; CTRP2	8.6543	10.4629	5.4567	0.2255
Capan-1	GDSC1; CTRP2	8.678	10.2707	5.5324	0.126
Capan-2	GDSC1; CTRP2	8.7997	10.4817	5.5034	0.1376
Panc 08.13	GDSC1; CTRP2	8.8203	10.4058	5.5366	0.1015
BxPC-3	GDSC1; CTRP2	8.8617	10.6354	5.4726	0.1616
KP-3	GDSC1; CTRP2	9.0354	10.8583	5.4581	0.1482
PK-45H	CTRP2	10.4436	22.6515	1.0588	12.7223
HPAF-II	GDSC1; CTRP2	10.7853	22.3473	0.5801	10.0068
YAPC	GDSC1; CTRP2	11.4691	25.4302	-1.2405	11.339
CFPAC-1	GDSC1; CTRP2	13.7552	30.2395	-0.3905	12.9257
-----------


⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYSE-50	GDSC1	2.9749	4.595	2.1815	6.5468
TE-12	GDSC1	3.5577	9.826	0.0399	19.6697
HCE-4	GDSC1	3.8773	6.0797	2.1155	4.3634
KYSE-220	GDSC1	4.852	6.6821	2.3788	1.0699
-----------

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; CTRP2	7.5667	16.3781	2.0849	13.4967
-----------

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-N-MC-IXC	GDSC1	2.8729	6.8917	0.9473	16.3482
SJNB-6	GDSC1	3.3033	13.9064	-2.2026	30.0152
SJNB-12	GDSC1	3.6991	6.3313	1.8749	6.628
GI-ME-N	GDSC1	4.201	30.96	-9.9922	39.5722
SJNB-10	GDSC1	4.5034	6.8932	2.1175	3.0428
KP-N-YS	GDSC1	4.6488	7.8584	1.7686	5.0919
SK-N-BE(2)-M17	GDSC1	4.679	6.8392	2.2332	2.0466
SiMa	GDSC1	4.8306	7.3151	2.1094	2.5524
SJNB-13	GDSC1	4.8872	6.7822	2.3551	1.1458
LA-N-6	GDSC1	5.0236	6.5883	2.4859	0.5046
GOTO	GDSC1	5.0673	6.9757	2.3587	0.9607
SJNB-7	GDSC1	5.0974	6.8092	2.434	0.6382
SJNB-14	GDSC1	5.1012	6.4181	2.5756	0.2216
TGW	GDSC1	5.2119	6.6748	2.5266	0.2949
IMR-5	GDSC1	5.348	6.8812	2.5044	0.2964
NB(TU)1	GDSC1	5.4674	7.0611	2.4853	0.2971
SJNB-5	GDSC1	5.6771	7.3454	2.4626	0.2753
NH-12	GDSC1	5.8225	7.466	2.473	0.2124
SK-N-DZ	GDSC1; CTRP2	5.8245	17.3791	0.1927	22.9812
NB69	GDSC1	5.8871	7.9869	2.3146	0.5685
CHP-212	GDSC1; CTRP2	6.0986	11.1156	3.5538	10.3438
NH-6	CTRP2	7.0061	23.0252	-1.6585	25.4201
SK-N-FI	GDSC1; CTRP2	7.0442	8.6517	5.4495	1.1069
IMR-32	CTRP2	7.1778	8.689	5.5045	0.8065
MHH-NB-11	GDSC1; CTRP2	7.7901	9.6384	5.4101	0.6627
CHP-126	GDSC1; CTRP2	7.8815	10.3226	5.1728	1.296
SK-N-AS	GDSC1; CTRP2	8.165	9.5733	5.5885	0.1534
SK-N-BE(2)	CTRP2	8.2047	11.5347	4.8218	2.1753
KP-N-SI9s	CTRP2	8.4434	9.7134	5.6392	0.0602
KP-N-YN	GDSC1; CTRP2	8.508	10.4821	5.3931	0.3738
SK-N-SH	GDSC1; CTRP2	8.7164	10.3326	5.5249	0.1279
Kelly	GDSC1; CTRP2	9.7875	19.4749	2.1337	10.0471
NB1	GDSC1; CTRP2	11.6223	22.4792	1.8788	8.7176
-----------


⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuCC-T1	GDSC1; CTRP2	6.1411	7.6562	5.3176	2.8731
SNU-869	CTRP2	7.6633	10.9295	4.7829	2.8726
SNU-478	CTRP2	7.6814	9.5381	5.3999	0.7579
HuH-28	CTRP2	7.8596	9.3763	5.5414	0.3203
SNU-308	CTRP2	8.4905	20.4624	0.7585	16.4748
SNU-1196	CTRP2	8.5529	9.9522	5.5968	0.0818
-----------


⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 90 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
OCUB-M	GDSC1	-0.193	7.7893	-2.3893	44.9622
MDA-MB-330	GDSC1	2.6942	6.4836	0.9972	16.6917
EFM-192A	GDSC1	3.0627	5.0159	2.0438	7.3161
MDA-MB-415	GDSC1	3.4276	4.938	2.3601	3.692
EFM-19	GDSC1	3.6686	9.5583	0.2601	18.0109
AU565	GDSC1; CTRP2	3.7759	8.3823	2.691	19.1571
MDA-MB-436	GDSC1	3.8895	5.434	2.42	2.1836
MDA-MB-175-VII	GDSC1	4.178	6.2596	2.2157	3.0001
MDA-MB-157	GDSC1; CTRP2	4.2061	6.6732	3.8372	13.5763
HCC2157	GDSC1	4.234	6.6209	2.0853	3.7788
HCC1187	GDSC1	4.3336	8.0251	1.4931	7.7529
HCC1428	GDSC1; CTRP2	4.6668	8.8156	3.392	14.1184
HCC1599	GDSC1	4.6763	6.5179	2.3641	1.3298
Evsa-T	GDSC1	5.0579	6.5504	2.513	0.4007
COLO 824	GDSC1	5.1504	8.0926	1.9437	3.0533
BT-483	GDSC1	5.201	7.0976	2.3686	0.8113
HCC1569	GDSC1	5.209	8.9779	1.5894	5.1679
MFM-223	GDSC1	5.3243	7.4532	2.2854	1.0526
UACC-893	GDSC1	5.4338	16.6128	-1.9	22.9771
HCC2218	GDSC1	5.462	7.1636	2.4472	0.3948
UACC-812	GDSC1	5.5194	7.3752	2.3934	0.5216
HCC70	GDSC1	5.6518	21.0909	-3.9417	28.4244
ZR-75-1	CTRP2	5.7988	7.0947	3.6626	0.2417
Hs 578Bst	CTRP2	5.8651	6.5923	5.6097	2.2053
CAL-85-1	GDSC1; CTRP2	6.3744	7.9583	5.3466	2.3542
HCC1143	CTRP2	6.4518	9.601	2.9625	1.9295
BT-20	GDSC1; CTRP2	6.5447	9.6903	4.6198	5.0891
MRK-nu-1	GDSC1	6.7029	25.5914	-5.3779	29.2935
KPL-1	CTRP2	6.7601	7.5285	5.7801	0.327
MCF-7	GDSC1; CTRP2	6.9367	9.0375	4.3178	0.8834
MDA-MB-453	GDSC1; CTRP2	6.9724	13.8389	2.8909	11.4421
CAL-120	GDSC1; CTRP2	7.3866	8.874	5.5301	0.5818
HCC1806	GDSC1; CTRP2	7.4958	8.9497	4.5776	0.1148
DU4475	GDSC1; CTRP2	7.6341	9.3633	5.4484	0.653
HMC-1-8	CTRP2	7.6612	8.8949	5.6397	0.2043
JIMT-1	GDSC1; CTRP2	7.6663	9.0917	5.5687	0.3409
CAMA-1	GDSC1; CTRP2	7.6709	17.2924	0.9472	12.9839
HCC1954	GDSC1; CTRP2	7.6826	9.287	4.5285	0.1387
HCC1419	GDSC1; CTRP2	7.7748	9.7113	5.3737	0.7712
CAL-148	GDSC1; CTRP2	7.9382	9.2644	5.6131	0.1708
BT-474	GDSC1; CTRP2	7.9455	9.2462	5.6223	0.1558
MDA-MB-361	GDSC1; CTRP2	8.1094	9.5955	5.5598	0.2079
MDA-MB-231	GDSC1; CTRP2	8.228	10.5045	5.2651	0.7916
HCC1500	GDSC1; CTRP2	8.3365	9.9676	5.5131	0.2205
HCC202	GDSC1; CTRP2	8.3409	11.3697	4.9644	1.5898
HDQ-P1	GDSC1; CTRP2	8.341	9.8731	5.5483	0.1693
BT-549	GDSC1; CTRP2	8.4094	10.0133	5.5243	0.1868
Hs 578T	GDSC1; CTRP2	8.4196	10.473	5.3605	0.4719
HCC1937	GDSC1; CTRP2	8.4731	10.3648	5.4224	0.3317
HCC38	GDSC1; CTRP2	8.481	10.4952	5.3774	0.4137
SK-BR-3	CTRP2	8.6173	10.3111	5.4965	0.1793
MDA-MB-468	GDSC1; CTRP2	8.6846	10.1843	5.5642	0.0941
T-47D	GDSC1; CTRP2	8.7569	10.6251	5.4377	0.2285
CAL-51	GDSC1; CTRP2	8.762	10.0648	5.6304	0.0402
HCC1395	GDSC1; CTRP2	9.0352	10.6704	5.5219	0.0883
ZR-75-30	GDSC1; CTRP2	10.9281	22.1573	1.6031	10.3917
BT 416	CTRP2	4.8742	20.6401	-2.2502	30.7054
BT 248	CTRP2	5.66	6.6639	5.3759	3.6518
BT 498	CTRP2	5.8494	6.6459	5.5689	2.4096
BT 444	CTRP2	5.9114	6.5702	5.6638	1.8765
BT 428	CTRP2	6.0502	20.5616	-1.2094	26.1678
BT147	CTRP2	6.1388	7.8203	5.2338	3.2295
BT 359	CTRP2	7.1812	8.6807	5.5097	0.7873
BT 340	CTRP2	7.1951	8.6338	5.5363	0.6943
BT 320	CTRP2	7.3499	8.3901	5.7015	0.194
BT164	CTRP2	7.4392	11.3353	4.4515	4.4321
BT 482	CTRP2	7.6436	8.9237	5.6221	0.2417
BT 504	CTRP2	7.707	22.4536	-0.8192	22.2153
BT 422	CTRP2	7.7321	8.971	5.6396	0.1838
BT 330	CTRP2	7.7534	9.3749	5.4973	0.4628
BT 159	CTRP2	7.7896	13.9118	3.4531	7.9038
BT 333	CTRP2	7.8022	9.1686	5.5952	0.2383
BT 328	CTRP2	7.8268	9.0004	5.6648	0.1243
BT 139	CTRP2	7.8468	8.9593	5.6863	0.0946
BT 239	CTRP2	7.8573	9.2692	5.5801	0.2476
BT 131	CTRP2	7.8644	9.1789	5.6156	0.1858
BT 228	CTRP2	7.9189	9.2439	5.6131	0.1755
BT 216	CTRP2	7.9224	9.4079	5.5551	0.2716
BT 172	CTRP2	7.9382	9.4737	5.5371	0.2999
BT 271	CTRP2	8.1962	9.7594	5.5342	0.2248
BT 232	CTRP2	8.3204	9.7156	5.5955	0.1158
BT 245	CTRP2	8.5294	10.0339	5.5607	0.1195
BT 187	CTRP2	8.5296	10.0897	5.5416	0.1407
BT 224	CTRP2	8.5549	14.5107	3.6758	5.9973
BT 231	CTRP2	8.659	10.5398	5.4311	0.2627
BT 179	CTRP2	9.2295	24.4643	-0.6648	19.3837
BT 286	CTRP2	10.1709	23.9281	0.2641	15.4742
BT 440	CTRP2	10.2363	24.3983	0.0824	15.9027
BT 112	CTRP2	10.2549	25.3079	-0.3441	17.0531
BT 145	CTRP2	10.2818	22.5181	1.015	13.072
-----------


⏷ Show the Full List of 90 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	6.4279	7.4706	4.7028	0.1787
-----------

Cancer Drug Sensitivity Data Curated from 65 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LNZTA3WT4	GDSC1	2.8919	3.7857	2.5138	4.245
D-542MG	GDSC1	3.0098	18.5837	-4.7837	36.551
GI-1	GDSC1	3.0646	10.7474	-0.82	25.7436
D-423MG	GDSC1	3.5263	6.6437	1.596	9.2632
KNS-81-FD	GDSC1	3.6762	7.0502	1.507	9.473
D-566MG	GDSC1	3.8058	7.7903	1.2387	11.0548
MOG-G-CCM	GDSC1	3.9953	6.1895	2.1387	3.9198
SK-MG-1	GDSC1	4.1002	7.4726	1.6008	7.5778
KS-1 [Human Krukenberg tumour]	GDSC1	4.1302	28.2313	-8.6866	38.635
D-263MG	GDSC1	4.1737	8.0808	1.3587	9.1328
H4	GDSC1	4.3029	7.589	1.6792	6.4978
SF539	GDSC1; CTRP2	4.3382	5.2039	4.3279	11.4015
Onda 10	GDSC1	4.4825	9.3678	0.9509	11.127
SF268	GDSC1; CTRP2	4.6863	5.6162	4.6534	9.1597
M059J	GDSC1	4.7495	6.7609	2.3002	1.5782
LN-405	GDSC1	5.0602	6.6294	2.4853	0.4852
KNS-60	CTRP2	5.1925	18.394	-0.8539	27.0595
D283 Med	GDSC1; CTRP2	5.2294	15.0145	0.8633	22.204
Onda 11	GDSC1	5.4581	16.4822	-1.8185	22.6194
GB-1	GDSC1; CTRP2	5.4778	6.2569	5.3573	4.2098
KINGS-1	GDSC1	5.5768	26.09	-6.4741	33.3081
U-251MG	GDSC1; CTRP2	5.6777	6.4754	5.479	3.1945
PFSK-1	GDSC1	5.6924	7.604	2.3775	0.4817
D-392MG	GDSC1	5.7188	13.6733	-0.2763	15.208
D-502MG	GDSC1	5.7765	7.8942	2.3053	0.6574
Daoy	GDSC1; CTRP2	5.804	7.3315	5.1909	4.08
Hs 683	GDSC1; CTRP2	6.0852	6.9626	5.6188	1.7117
MOG-G-UVW	GDSC1	6.1344	17.6559	-1.9087	21.3216
SNU-626	CTRP2	6.4049	7.825	5.4337	1.949
SNU-466	CTRP2	6.4846	12.8456	2.2693	9.7164
AM-38	GDSC1; CTRP2	6.5205	8.857	5.0124	3.5007
SNU-1105	CTRP2	6.6606	8.4256	4.4356	0.7195
CAS-1	GDSC1; CTRP2	6.9953	8.8058	5.3526	1.7384
SNU-738	CTRP2	7.1364	8.9459	5.3709	1.2921
U-87MG ATCC	GDSC1; CTRP2	7.2493	9.1307	4.4189	0.4485
LN-18	GDSC1; CTRP2	7.4235	8.5289	5.6797	0.2095
CCF-STTG1	CTRP2	7.674	8.797	5.6797	0.1376
TM-31	CTRP2	7.8522	8.9716	5.684	0.0963
GMS-10	CTRP2	7.8925	9.1591	5.6333	0.1525
YH-13	GDSC1; CTRP2	7.8954	14.6299	3.1793	8.8215
YKG-1	GDSC1; CTRP2	7.9421	9.2073	5.6347	0.1395
DK-MG	GDSC1; CTRP2	8.0165	9.3387	5.616	0.1485
NMC-G1	GDSC1; CTRP2	8.0239	9.5055	5.5593	0.2324
M059K	CTRP2	8.0286	9.7165	5.4834	0.3728
U-118MG	GDSC1; CTRP2	8.0958	9.5176	5.5824	0.1774
SNU-489	CTRP2	8.1034	9.2685	5.6714	0.072
SF295	GDSC1; CTRP2	8.1483	9.4309	5.6319	0.1044
LN-229	GDSC1; CTRP2	8.2695	9.7795	5.5547	0.1762
T98G	GDSC1; CTRP2	8.2742	10.3657	5.3399	0.5818
SW1783	GDSC1; CTRP2	8.2901	10.233	5.3973	0.4474
SW1088	GDSC1; CTRP2	8.3312	9.9286	5.525	0.2041
8-MG-BA	GDSC1; CTRP2	8.3339	9.9777	5.5085	0.2283
ONS-76	GDSC1; CTRP2	8.349	9.9465	5.5253	0.1993
SNU-201	CTRP2	8.3868	9.7495	5.6075	0.0935
GOS-3	CTRP2	8.4897	14.1079	3.8226	5.5211
42-MG-BA	GDSC1; CTRP2	8.5143	9.9104	5.5975	0.0859
GaMG	GDSC1; CTRP2	8.5476	10.0116	5.5748	0.1025
Becker	GDSC1; CTRP2	8.5679	15.7958	3.0775	8.2529
A-172	GDSC1; CTRP2	8.6098	10.3869	5.467	0.2213
SNB-75	GDSC1; CTRP2	8.6293	10.4995	5.4342	0.2658
KNS-81	CTRP2	9.0254	28.5068	-2.8095	24.5495
DBTRG-05MG	GDSC1; CTRP2	9.0291	10.6897	5.5133	0.0961
KNS-42	GDSC1; CTRP2	9.3486	19.3289	1.9131	11.3957
SF126	GDSC1; CTRP2	9.5211	17.9793	2.6658	8.516
KALS-1	GDSC1; CTRP2	11.3785	22.8103	1.5798	9.9376
-----------


⏷ Show the Full List of 65 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TGBC1TKB	GDSC1	3.3338	5.5639	1.9846	6.8744
TGBC24TKB	GDSC1	3.5557	7.0991	1.3931	10.6976
ETK-1	GDSC1	3.5619	6.5594	1.6641	8.6353
-----------

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHUEM-1	CTRP2	5.6392	6.3152	5.5071	3.1862
MFE-280	GDSC1	5.8119	8.1133	2.2388	0.864
HEC-1-A	CTRP2	6.4174	7.9158	5.3984	2.0744
JHUEM-7	CTRP2	6.6641	9.0557	5.0187	3.2519
HEC-1-B	CTRP2	7.2276	9.2211	4.3755	0.5589
HEC-265	CTRP2	7.3958	8.5596	5.657	0.265
ESS-1	GDSC1; CTRP2	7.427	9.2742	5.3842	0.9889
HEC-251	CTRP2	7.8103	9.9599	5.289	0.9924
RL95-2	CTRP2	7.9194	15.4852	2.7807	10.3254
JHUEM-2	CTRP2	8.0927	9.8009	5.4781	0.3589
JHUEM-3	CTRP2	8.1555	10.1715	5.3636	0.5836
EFE-184	CTRP2	8.1768	9.4458	5.6369	0.0947
EN	GDSC1; CTRP2	8.1897	9.4521	5.6394	0.0904
HEC-6	CTRP2	8.2354	9.3022	5.7052	0.0353
KLE	GDSC1; CTRP2	8.2606	10.1477	5.4171	0.4178
MFE-296	GDSC1; CTRP2	8.3653	10.2101	5.4364	0.3418
MFE-319	GDSC1; CTRP2	8.4208	10.1984	5.4625	0.2783
HEC-151	CTRP2	8.4765	9.7758	5.6297	0.0639
HEC-59	CTRP2	8.5436	10.0074	5.5748	0.103
HEC-50B	CTRP2	8.6177	10.228	5.5256	0.1436
AN3-CA	GDSC1; CTRP2	8.9307	10.8074	5.4379	0.1907
HEC-108	CTRP2	14.5878	29.6534	0.3703	10.1003
Ishikawa (Heraklio) 02 ER-	CTRP2	6.6881	8.9234	5.0996	2.8873
-----------


⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RXF 393L	GDSC1	1.9074	20.2638	-6.5585	41.5427
A-704	GDSC1	2.3959	4.5241	1.6903	12.7414
BB65-RCC	GDSC1	3.2357	6.5834	1.4008	11.6992
SW13	GDSC1	3.4913	5.1661	2.294	4.0201
SW156	GDSC1	3.6756	5.563	2.2284	4.0291
LB996-RCC	GDSC1	3.7309	8.1876	0.9873	13.0752
LB1047-RCC	GDSC1	3.7382	17.2733	-3.5311	32.2049
HA7-RCC	GDSC1	4.0887	6.4421	2.0794	4.1325
SN12C	GDSC1	4.1296	11.9788	-0.5863	21.1089
LB2241-RCC	GDSC1	4.3955	7.4388	1.8077	5.3693
A-498	GDSC1	4.5448	16.269	-2.3952	26.9635
UO-31	GDSC1; CTRP2	4.5806	5.5998	4.5426	9.8811
BFTC-909	GDSC1; CTRP2	4.8073	6.1034	4.6777	8.6971
VMRC-RCZ	GDSC1; CTRP2	6.0655	7.1142	5.527	2.1345
TK-10	GDSC1	6.1466	8.5991	2.1935	0.8079
TUHR14TKB	CTRP2	6.2168	7.8848	5.2636	2.9639
769-P	GDSC1; CTRP2	7.3142	8.8736	4.5381	0.2028
TUHR4TKB	CTRP2	7.4788	9.0658	5.4958	0.6189
KMRC-1	GDSC1; CTRP2	7.7379	9.4005	5.4806	0.5109
TUHR10TKB	CTRP2	7.8282	8.7865	5.7384	0.0483
KMRC-2	CTRP2	7.8742	9.2637	5.5888	0.2271
RCC10RGB	GDSC1; CTRP2	7.9747	9.1315	5.6728	0.0886
KMRC-3	CTRP2	8.1756	10.4836	5.2494	0.8645
KMRC-20	GDSC1; CTRP2	8.2597	9.984	5.4775	0.3018
SNU-1272	CTRP2	8.2648	9.7839	5.5514	0.182
Caki-2	CTRP2	8.2895	9.6398	5.6105	0.1047
786-O	GDSC1; CTRP2	8.3249	11.667	4.8291	2.0423
OS-RC-2	GDSC1; CTRP2	8.3487	10.0182	5.4996	0.2382
VMRC-RCW	GDSC1; CTRP2	8.4808	10.194	5.487	0.2234
CAL-54	GDSC1; CTRP2	8.7307	10.7227	5.3929	0.3042
Caki-1	GDSC1; CTRP2	8.7968	10.5817	5.4677	0.1797
ACHN	GDSC1; CTRP2	8.8591	10.6285	5.4741	0.1604
-----------


⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 53 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
GP5d	GDSC1	2.5091	3.6511	2.2101	8.2704
HCC2998	GDSC1	3.2233	4.786	2.2856	4.8759
SW626	GDSC1	3.3222	4.9324	2.2875	4.5547
SW837	GDSC1	3.8211	5.4644	2.3662	2.691
CaR-1	GDSC1	4.3799	12.4941	-0.6519	20.6693
COLO 320HSR	GDSC1	4.7298	8.1298	1.6931	5.4359
RCM-1 [Human ESC]	GDSC1; CTRP2	4.8488	5.8081	4.7957	8.1472
LoVo	GDSC1; CTRP2	5.7212	9.3964	2.6395	4.0933
MDST8	GDSC1; CTRP2	5.8458	7.1992	3.643	0.2642
SW1463	GDSC1; CTRP2	6.0031	7.1641	5.4498	2.5804
HCC-56	CTRP2	6.4949	8.1765	5.3265	2.2512
NCI-H747	GDSC1; CTRP2	6.6294	8.8638	5.0875	3.0238
SW1417	GDSC1; CTRP2	6.8754	8.8389	5.2641	1.9801
HT-29	GDSC1; CTRP2	6.9486	9.4614	5.018	2.8495
C2BBe1	GDSC1; CTRP2	7.0553	9.0726	5.2668	1.7561
HCT 15	GDSC1; CTRP2	7.0902	9.5358	5.0743	2.446
DLD-1	CTRP2	7.1317	8.2846	5.6487	0.4145
CCK-81	GDSC1; CTRP2	7.2675	9.5681	4.2578	0.8446
SNU-503	CTRP2	7.3577	16.095	2.0672	13.9147
CW-2	GDSC1; CTRP2	7.4961	10.3745	4.9362	2.4899
OUMS-23	CTRP2	7.5343	8.517	5.7265	0.1047
HCT 116	GDSC1; CTRP2	7.6771	9.9797	5.2131	1.3342
LS1034	GDSC1; CTRP2	7.7094	9.059	5.5986	0.2634
HCT 8	CTRP2	7.7156	8.7796	5.7011	0.1007
COLO 678	GDSC1; CTRP2	7.7165	9.3334	5.4973	0.4811
SNU-C4	CTRP2	7.7585	8.8974	5.6757	0.1242
COLO205	GDSC1; CTRP2	7.772	8.8903	5.6831	0.1119
KM12	GDSC1; CTRP2	7.8324	19.2066	0.8875	17.1423
LS411N	GDSC1; CTRP2	7.8828	9.0749	5.6593	0.12
HT115	GDSC1; CTRP2	7.9184	9.1065	5.6612	0.1108
SW48	GDSC1; CTRP2	7.959	9.5591	5.5138	0.338
SW948	GDSC1; CTRP2	7.9776	9.2043	5.6487	0.1148
LS180	GDSC1; CTRP2	8.0107	9.4762	5.5648	0.2271
SNU-81	CTRP2	8.0126	9.4838	5.5628	0.2299
SNU-C2A	CTRP2	8.0576	10.2744	4.32	0.3545
GP2d	CTRP2	8.0865	9.5926	5.5521	0.2264
HT-55	GDSC1; CTRP2	8.1608	9.4221	5.6394	0.0946
NCI-H508	CTRP2	8.1826	10.119	5.3955	0.4971
LS123	GDSC1; CTRP2	8.2081	9.8764	5.4965	0.2845
SNU-61	CTRP2	8.21	9.6064	5.5934	0.138
SK-CO-1	CTRP2	8.3131	9.9873	5.4971	0.2521
LS513	GDSC1; CTRP2	8.316	9.8226	5.5567	0.1634
SW620	GDSC1; CTRP2	8.4684	9.7595	5.6324	0.0628
T84	GDSC1; CTRP2	8.494	10.2047	5.4882	0.2184
SNU-1033	CTRP2	8.5252	10.4542	5.4102	0.3368
CL-11	GDSC1; CTRP2	8.542	10.4176	5.4301	0.297
NCI-H716	GDSC1; CTRP2	8.584	18.6275	1.7232	13.1607
SNU-C5	CTRP2	8.7745	10.3634	5.5349	0.1092
SNU-C2B	GDSC1	8.9282	25.8198	-3.9279	21.9888
SNU-C1	GDSC1; CTRP2	8.9604	17.6604	2.45	10.0368
COLO201	CTRP2	9.036	18.1186	2.2817	10.537
SNU-407	CTRP2	9.1493	10.9188	5.4777	0.1124
RKO	GDSC1; CTRP2	11.4997	26.5882	-0.1143	14.7908
-----------


⏷ Show the Full List of 53 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1	3.9724	5.9197	2.2489	3.1908
-----------

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHH-1	GDSC1	1.9575	7.2267	-0.0346	26.393
JHH-7	GDSC1	2.7698	3.4362	2.5694	4.3333
HLE	GDSC1	3.3269	4.9333	2.2904	4.5176
Hep-G2/C3A	GDSC1	3.6742	14.3874	-2.1421	28.6709
Huh-7	GDSC1	3.7777	5.2275	2.4482	2.2125
JHH-5	CTRP2	5.3125	6.0891	5.233	5.1557
Hep-G2	CTRP2	5.7659	7.567	3.468	0.7623
SNU-182	CTRP2	5.9877	7.7184	5.1597	3.8296
SNU-761	CTRP2	6.2598	13.0117	2.7385	13.3417
Hep 3B2.1-7	GDSC1; CTRP2	6.6177	9.3088	4.0367	2.1357
SNU-475	GDSC1	6.6714	15.3402	-0.4447	13.8977
JHH-6	GDSC1; CTRP2	7.2895	8.4831	5.6411	0.3484
SK-HEP-1	GDSC1; CTRP2	7.6491	8.7663	5.6812	0.1413
HuH-1	GDSC1; CTRP2	7.6703	8.8916	5.6444	0.1936
HuH-6	CTRP2	7.7625	10.5697	5.0023	1.9712
SNU-398	GDSC1; CTRP2	7.9693	15.2773	2.9171	9.7266
HLF	CTRP2	8.0261	9.3993	5.5982	0.1978
SNU-886	CTRP2	8.1972	10.0443	5.4298	0.4814
JHH-2	GDSC1; CTRP2	8.2489	9.7757	5.5483	0.19
SNU-387	GDSC1; CTRP2	8.2634	9.9304	5.4984	0.2643
SNU-423	GDSC1; CTRP2	8.3316	10.1886	5.4308	0.364
PLC/PRF/5	CTRP2	8.3842	9.7543	5.6049	0.0964
SNU-449	GDSC1; CTRP2	8.4718	10.225	5.4725	0.2479
JHH-4	GDSC1; CTRP2	8.7149	10.2399	5.556	0.0976
Li-7	CTRP2	8.7349	10.7291	5.3922	0.3042
-----------


⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 208 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-427	GDSC1	1.5838	6.2128	0.1014	27.4325
NCI-H2795	GDSC1	2.7696	4.4118	2.0939	8.0262
NCI-H1915	GDSC1; CTRP2	2.8218	3.8827	2.4026	3.6101
NCI-H522	GDSC1	2.9849	4.2972	2.3388	5.2697
LC-2/ad	GDSC1	3.0596	5.5402	1.7792	9.4037
NCI-H1651	GDSC1	3.0944	5.7675	1.6941	9.9429
NCI-H3122	GDSC1	3.1131	4.5415	2.3214	4.956
PaCa-3	GDSC1	3.1504	4.9694	2.1377	6.2751
NCI-H1944	GDSC1	3.1536	4.8551	2.1971	5.7968
COR-L23	GDSC1	3.1652	5.2822	1.9935	7.3571
SBC-3	GDSC1	3.1844	4.5505	2.3726	4.3194
UMC-11	GDSC1	3.2127	4.6348	2.3524	4.3869
NCI-H1437	GDSC1	3.3244	4.9347	2.2879	4.5445
NCI-H64	GDSC1	3.6252	5.1103	2.4093	2.8216
NCI-H596	GDSC1	3.6333	5.1902	2.3769	3.0379
NCI-H3255	GDSC1	3.6375	6.1378	1.9254	6.419
NCI-H2135	GDSC1	3.6779	9.1398	0.4751	16.6563
RERF-LC-KJ	GDSC1	3.7214	6.8953	1.616	8.5208
NCI-H1648	GDSC1	3.7537	8.9222	0.6412	15.3427
Lu-135	GDSC1	3.8279	5.7187	2.2531	3.4802
NCI-H847	GDSC1	3.8617	5.3083	2.4602	1.9682
NCI-H345	GDSC1	3.8969	5.2654	2.4986	1.6553
ABC-1	GDSC1	4.0037	6.0525	2.207	3.4175
NCI-H1781	GDSC1	4.166	5.7878	2.416	1.7285
NCI-H226	GDSC1	4.1885	5.6744	2.4753	1.3449
NCI-H720	GDSC1	4.1961	5.4649	2.5645	0.8567
NCI-H290	GDSC1	4.2148	6.2332	2.2483	2.7126
NCI-H2731	GDSC1	4.2424	6.2259	2.2669	2.5402
NCI-H1993	GDSC1	4.2998	9.783	0.6213	13.8021
NCI-H82	GDSC1	4.318	7.9529	1.517	7.6213
HOP-92	GDSC1	4.3814	7.2888	1.8682	4.9754
NCI-H2087	GDSC1; CTRP2	4.4398	6.8164	4.0352	12.163
NCI-H1836	GDSC1	4.4771	7.0424	2.0366	3.6232
NCI-H1581	GDSC1; CTRP2	4.4784	5.9209	4.3675	10.8179
NCI-H1155	GDSC1; CTRP2	4.4941	5.9546	4.3762	10.7383
IST-SL1	GDSC1	4.509	8.1746	1.5362	7.017
HCC44	GDSC1; CTRP2	4.5387	7.9083	3.6812	13.2801
HOP-62	GDSC1; CTRP2	4.5615	6.0348	4.4286	10.3439
NCI-H1688	GDSC1	4.6098	6.4634	2.3549	1.4586
NCI-H1048	GDSC1	4.6263	6.3209	2.42	1.1043
NCI-H187	GDSC1	4.6305	5.8765	2.5911	0.389
NCI-H2869	GDSC1	4.6776	7.2059	2.0757	3.0063
Ms-1	GDSC1	4.709	7.3459	2.0318	3.2312
SW1573	GDSC1	4.7231	8.2061	1.6542	5.7153
NCI-H1436	GDSC1	4.7417	6.2388	2.5018	0.6365
LB647-SCLC	GDSC1	4.7581	7.6066	1.9443	3.7062
SBC-5	GDSC1; CTRP2	4.8863	6.6705	4.5677	8.8803
NCI-H2373	GDSC1	4.9053	12.1619	-0.1066	16.3939
NCI-H2141	GDSC1	4.9449	6.4219	2.5157	0.453
NCI-H1092	GDSC1	4.9764	6.4443	2.5198	0.4226
LC-1/sq-SF	CTRP2	4.9769	13.2963	1.4945	20.6634
IST-SL2	GDSC1	4.9839	7.708	2.0214	2.8449
HCC33	GDSC1	5.0065	6.4831	2.5174	0.4139
NCI-H2227	GDSC1	5.0742	6.9649	2.3658	0.9247
NCI-H1693	GDSC1	5.0749	13.3874	-0.5825	18.3793
NCI-H748	GDSC1	5.0882	7.3693	2.2132	1.6286
NCI-H1793	GDSC1; CTRP2	5.1043	6.1339	4.9926	6.6573
NCI-H446	GDSC1; CTRP2	5.1419	8.8514	3.8325	11.1968
LC-1/sq	GDSC1	5.1582	8.4707	1.7849	4.0154
NCI-H2595	GDSC1	5.1583	7.7039	2.1104	2.0874
DV-90	CTRP2	5.166	6.1209	5.0639	6.212
NCI-H1770	GDSC1	5.1847	6.7587	2.4867	0.4145
NCI-H810	GDSC1; CTRP2	5.1881	14.4819	1.0923	21.554
T3M-10	CTRP2	5.1957	8.1452	4.2237	9.4651
NCI-H2347	GDSC1	5.1964	9.8616	1.181	7.8541
NCI-H524	GDSC1	5.2209	7.4405	2.2452	1.3284
NCI-H2106	CTRP2	5.2259	6.1837	5.1095	5.8665
NCI-H2818	GDSC1	5.2321	7.413	2.261	1.2443
NCI-H358	GDSC1; CTRP2	5.2788	6.8279	4.915	6.4669
RERF-LC-A1	CTRP2	5.3048	6.796	4.9557	6.2383
Lu-165	GDSC1	5.3231	6.9447	2.4727	0.388
NCI-H211	GDSC1; CTRP2	5.3458	6.2781	5.2075	5.1521
NCI-H1975	GDSC1	5.3515	7.261	2.369	0.7026
NCI-H2803	GDSC1	5.3668	7.1877	2.4021	0.5792
NCI-H1304	GDSC1	5.3858	6.7923	2.5487	0.1902
Lu-139	GDSC1	5.4035	6.9757	2.4917	0.3058
DMS 79	GDSC1	5.4306	7.0569	2.4732	0.3404
NCI-H1694	GDSC1; CTRP2	5.4409	6.2985	5.3023	4.5229
NCI-H510A	GDSC1	5.4617	7.0391	2.4909	0.2862
NCI-H1184	CTRP2	5.4683	9.2413	2.5505	4.8622
NCI-H2369	GDSC1	5.4748	14.8434	-1.0075	19.3059
NCI-H2444	GDSC1; CTRP2	5.5104	8.0485	4.5687	7.3165
NCI-H322M	GDSC1	5.5573	8.3933	2.0193	2.0797
Lu-99A	GDSC1	5.5765	7.5697	2.3451	0.6436
NCI-H1876	GDSC1	5.5775	7.4184	2.4002	0.4721
ChaGo-K-1	GDSC1; CTRP2	5.6385	8.2053	4.6095	6.8635
Lu-99	CTRP2	5.6404	6.1251	5.5791	2.9095
NCI-H1703	GDSC1	5.7157	23.1261	-4.8992	30.3451
NCI-H2461	GDSC1	5.7206	14.4161	-0.6308	16.9622
NCI-H1563	GDSC1; CTRP2	5.7685	6.3531	5.6259	2.3757
NCI-H2170	GDSC1; CTRP2	5.7736	6.8532	5.3969	3.2935
NCI-H513	GDSC1	5.823	7.5019	2.461	0.2345
NCI-H1963	GDSC1	5.8753	8.0164	2.2994	0.6209
NCI-H2126	CTRP2	5.9056	7.1888	3.6698	0.1946
NCI-H2023	GDSC1; CTRP2	5.9289	12.1916	1.4484	9.0847
NCI-H1435	GDSC1; CTRP2	5.9326	8.7267	3.0651	2.0511
DMS 454	CTRP2	6.0121	7.6448	5.2172	3.54
NCI-H2291	GDSC1; CTRP2	6.0133	8.1313	4.2142	2.1458
COR-L51	CTRP2	6.0566	7.8308	5.1613	3.6882
SBC-1	GDSC1	6.0808	16.3691	-1.3239	19.1787
HCC15	GDSC1; CTRP2	6.147	9.3531	4.4748	6.4021
HCC1438	CTRP2	6.1754	7.1418	5.6007	1.6271
NCI-H2722	GDSC1	6.1761	16.9938	-1.5594	19.9037
VMRC-LCD	CTRP2	6.2018	9.0419	4.6747	5.4604
Lu-134-A	GDSC1	6.2446	8.1222	2.3982	0.237
NCI-H1568	GDSC1; CTRP2	6.2528	7.4506	5.5065	1.8892
LK-2	GDSC1	6.2578	19.1659	-2.5551	23.2458
LCLC-103H	GDSC1; CTRP2	6.2631	11.7806	2.63	8.5554
CPC-N	GDSC1	6.308	19.7995	-2.8279	23.9813
NCI-H2804	GDSC1	6.32	8.2336	2.3868	0.2379
RERF-LC-Ad1	CTRP2	6.3496	12.7608	2.2125	10.1853
HARA [Human squamous cell lung carcinoma]	GDSC1; CTRP2	6.3805	8.2905	5.1877	3.0022
KNS-62	CTRP2	6.3865	8.0265	5.322	2.4368
NCI-H1341	CTRP2	6.5884	15.9267	1.5489	17.1524
LUDLU-1	CTRP2	6.632	12.6272	3.2289	10.6882
DMS 53	GDSC1	6.6469	19.663	-2.5227	22.2849
Calu-3	GDSC1; CTRP2	6.655	12.9255	3.0986	11.1732
NCI-H1734	GDSC1; CTRP2	6.6727	8.6012	4.3699	0.9105
RERF-LC-Sq1	GDSC1	6.674	8.796	2.3199	0.2659
NCI-H2591	GDSC1	6.7123	19.2351	-2.2707	21.3061
COR-L95	GDSC1; CTRP2	6.7275	13.5652	2.837	12.0861
LXF 289	GDSC1; CTRP2	6.8687	13.2646	1.5578	7.1607
MOR/CPR	CTRP2	6.8963	14.637	2.4358	13.3432
NCI-H2405	GDSC1; CTRP2	6.9719	10.4756	3.7173	2.9728
LK2	CTRP2	7.1086	7.8697	5.7964	0.1045
NCI-H441	GDSC1; CTRP2	7.3876	9.0444	4.505	0.2354
NCI-H650	GDSC1; CTRP2	7.4874	9.0265	4.5482	0.1506
COLO 699	CTRP2	7.5824	10.51	4.0252	1.3195
RERF-LC-Ad2	CTRP2	7.7263	9.4034	5.4743	0.5325
NCI-H1755	GDSC1; CTRP2	7.7299	9.7567	5.3337	0.9165
LOU-NH91	GDSC1; CTRP2	7.7318	9.2948	5.5189	0.4227
NCI-H460	GDSC1; CTRP2	7.7365	9.0938	5.5966	0.2577
Sq-1	CTRP2	7.7436	14.4825	3.1439	9.1891
SK-LU-1	GDSC1; CTRP2	7.7485	15.8242	2.4918	11.6901
NCI-H2029	GDSC1; CTRP2	7.7793	9.4125	5.494	0.458
NCI-H1650	GDSC1; CTRP2	7.8127	15.2746	2.8071	10.3891
COR-L88	GDSC1; CTRP2	7.8462	10.6774	5.0012	1.8949
HCC1588	CTRP2	7.8576	9.5814	5.4626	0.4941
NCI-H2196	GDSC1; CTRP2	7.8633	9.5227	5.4877	0.4334
NCI-H196	GDSC1; CTRP2	7.8771	9.1112	5.6444	0.1405
NCI-H2286	CTRP2	7.9296	9.3936	5.5632	0.2546
PC-14	GDSC1; CTRP2	7.9362	10.36	5.1847	1.2163
NCI-H2171	GDSC1; CTRP2	7.9593	9.3755	5.5814	0.2146
NCI-H1838	GDSC1; CTRP2	7.9974	10.1949	5.2826	0.884
Lu-65	GDSC1; CTRP2	8.0219	13.4765	3.819	6.1374
NCI-H526	GDSC1; CTRP2	8.0352	9.6206	5.5218	0.2952
NCI-H2172	GDSC1; CTRP2	8.0414	9.2542	5.6544	0.0974
NCI-H2110	GDSC1; CTRP2	8.0777	12.3984	4.3596	3.9832
NCI-H69	GDSC1; CTRP2	8.0779	10.2135	5.3125	0.7536
NCI-H1339	CTRP2	8.0829	9.7885	5.4787	0.3613
NCI-H2122	GDSC1; CTRP2	8.1013	9.5166	5.5848	0.1726
NCI-H2085	GDSC1; CTRP2	8.1209	10.2759	5.3072	0.7427
HCC1195	CTRP2	8.1297	9.7574	5.5091	0.2871
NCI-H1573	GDSC1; CTRP2	8.1308	9.7391	5.5162	0.2741
NCI-H23	GDSC1; CTRP2	8.1327	10.4794	5.2311	0.9419
IA-LM	GDSC1; CTRP2	8.1482	9.5978	5.5736	0.1776
COLO 668	GDSC1; CTRP2	8.1661	12.004	4.592	3.0236
HCC4006	CTRP2	8.1713	9.6141	5.5765	0.1682
NCI-H2030	GDSC1; CTRP2	8.1785	9.6284	5.5741	0.1699
NCI-H841	GDSC1; CTRP2	8.2011	9.628	5.5826	0.1535
NCI-H292	GDSC1; CTRP2	8.2048	9.7045	5.557	0.188
HCC78	GDSC1; CTRP2	8.2085	9.6787	5.5676	0.1722
Calu-1	CTRP2	8.2213	9.6774	5.5728	0.1623
NCI-H2081	GDSC1; CTRP2	8.2245	9.8444	5.5145	0.2489
NCI-H520	GDSC1; CTRP2	8.2414	10.1895	5.3934	0.4759
NCI-H889	CTRP2	8.2499	10.2308	5.3813	0.4988
RERF-LC-MS	GDSC1; CTRP2	8.2633	9.7571	5.5603	0.17
SHP-77	GDSC1; CTRP2	8.279	9.363	5.6998	0.0353
NCI-H2228	GDSC1; CTRP2	8.2844	36.4419	-7.3303	32.2933
HCC366	CTRP2	8.3169	10.0457	5.4774	0.2839
NCI-H1105	CTRP2	8.3394	18.956	1.387	14.6835
HCC2935	CTRP2	8.3706	9.6658	5.6301	0.0752
NCI-H1355	GDSC1; CTRP2	8.4155	10.3732	5.3962	0.4008
HCC827	GDSC1; CTRP2	8.4246	9.936	5.5569	0.1418
NCI-H1395	CTRP2	8.4412	11.7463	4.8561	1.8541
NCI-H1666	GDSC1; CTRP2	8.4528	10.1341	5.4978	0.2144
NCI-H1623	GDSC1; CTRP2	8.4989	10.5022	5.382	0.3982
HCC2108	CTRP2	8.5001	9.9774	5.5697	0.1147
NCI-H322	CTRP2	8.5406	10.0939	5.5441	0.1359
NCI-H1869	GDSC1; CTRP2	8.5612	10.4492	5.4261	0.2981
NCI-H838	GDSC1; CTRP2	8.5745	9.9508	5.6047	0.0728
NCI-H647	GDSC1; CTRP2	8.5759	10.8661	5.277	0.5866
SK-MES-1	GDSC1; CTRP2	8.6298	10.2355	5.5273	0.1395
HCC95	CTRP2	8.6539	10.1161	5.5765	0.087
EBC-1	GDSC1; CTRP2	8.6539	10.2123	5.5439	0.1178
NCI-H1299	GDSC1; CTRP2	8.6628	10.2536	5.5329	0.1279
NCI-H209	GDSC1; CTRP2	8.6644	11.0228	5.2547	0.597
DMS 114	GDSC1; CTRP2	8.7149	9.9681	5.6464	0.035
EPLC-272H	GDSC1; CTRP2	8.7501	10.6857	5.4136	0.2659
HCC1833	CTRP2	8.762	10.5835	5.4543	0.2044
LCLC-97TM1	GDSC1; CTRP2	8.7702	14.1564	3.972	4.6323
Calu-6	GDSC1; CTRP2	8.7873	18.6871	1.8374	12.4606
HCC1171	CTRP2	8.8406	10.7033	5.4413	0.2049
NCI-H727	GDSC1; CTRP2	8.8465	10.4906	5.5169	0.1165
DMS 273	GDSC1; CTRP2	8.8619	17.2856	2.563	9.7624
NCI-H2009	GDSC1; CTRP2	8.903	10.7526	5.4469	0.1849
SW1271	GDSC1; CTRP2	9.002	16.1077	3.2123	7.1768
NCI-H1373	CTRP2	9.0107	18.0973	2.2748	10.5968
A-549	GDSC1; CTRP2	9.0681	11.0156	5.4155	0.1917
EKVX	GDSC1; CTRP2	9.3909	11.5521	5.3464	0.2147
NCI-H2342	GDSC1; CTRP2	9.4015	19.5143	1.86	11.5048
NCI-H1792	GDSC1; CTRP2	9.4135	18.2785	2.4557	9.4053
BEN	GDSC1; CTRP2	10.7198	25.6475	-0.1875	15.997
COR-L105	GDSC1; CTRP2	10.7338	23.0521	1.0591	12.3477
CAL-12T	GDSC1; CTRP2	11.7861	27.8998	-0.5483	15.5892
NCI-H661	GDSC1; CTRP2	13.1768	27.0362	0.7285	10.5181
HCC2279	CTRP2	14.7374	33.5518	-1.3166	14.1651
Hs 888.Lu	CTRP2	8.5547	14.5438	3.6602	6.0567
-----------


⏷ Show the Full List of 208 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1	3.4724	5.397	2.1687	5.0296
-----------

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
P-STS	CTRP2	7.6672	20.0958	0.321	19.1613
H-STS	CTRP2	8.086	29.6209	-4.0886	28.2512
SYO-1	CTRP2	8.1746	10.0795	5.4071	0.4748
-----------

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	7.672	9.3156	5.4846	0.5358
Aska-SS	CTRP2	12.2822	31.4926	-1.9315	18.312
MFH-ino	GDSC1	2.0105	20.9948	-6.8347	41.5227
VA-ES-BJ	GDSC1	3.099	4.1316	2.5144	3.4857
SW872	GDSC1	3.5533	7.9787	0.9554	13.8718
Rh30	GDSC1	3.6559	7.0468	1.4938	9.634
A-204	GDSC1; CTRP2	4.2309	10.0401	2.3887	19.1469
EW-8	GDSC1	4.2744	6.1221	2.3295	2.0874
Hs 633.T	GDSC1	4.3356	12.685	-0.7794	21.4001
SW684	GDSC1	4.9668	6.388	2.5364	0.3775
KYM-1	GDSC1; CTRP2	5.3928	6.1786	5.2926	4.6981
GCT	GDSC1; CTRP2	5.6115	6.3971	5.4444	3.5051
STS-0421	GDSC1	5.6269	7.9955	2.2066	1.1289
TE 441.T	GDSC1; CTRP2	6.3014	8.455	5.046	3.7261
Rh41	GDSC1; CTRP2	6.3828	13.7164	2.4866	14.0915
Hs 729.T	CTRP2	6.4473	9.8416	4.4702	5.8784
BT-12	CTRP2	7.1886	8.0959	5.7454	0.167
MES-SA	GDSC1; CTRP2	7.7839	8.8369	5.7059	0.0836
RKN	GDSC1; CTRP2	7.9667	9.0181	5.7084	0.0569
HT-1080	GDSC1; CTRP2	7.9904	12.5089	4.2542	4.4901
TE 617.T	CTRP2	8.1292	15.2933	3.021	9.0894
Tm87-16	CTRP2	8.1394	10.5011	5.2254	0.9533
TTC-709	CTRP2	8.1412	19.9073	0.7734	16.9902
BT-16	CTRP2	8.1862	9.3046	5.6878	0.0501
SK-UT-1	GDSC1; CTRP2	8.3442	10.3483	5.3762	0.4697
RD	GDSC1; CTRP2	8.5559	10.6173	5.3624	0.4157
Rh18	CTRP2	8.6525	9.9802	5.6215	0.0534
SK-LMS-1	GDSC1; CTRP2	8.7262	10.3209	5.5323	0.1187
G-401	GDSC1; CTRP2	8.9865	11.1538	5.336	0.3248
G-402	GDSC1; CTRP2	9.7635	18.0509	2.7849	7.7919
SW982	GDSC1; CTRP2	12.5054	35.2927	-3.6081	21.4602
-----------


⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	8.3619	28.1214	-3.1273	26.1599
-----------

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	11.2851	26.8551	-0.3841	15.788
OC 314	GDSC1; CTRP2	4.4719	4.9775	4.4714	10.4778
A2780	GDSC1; CTRP2	4.4785	6.2261	4.2826	11.1252
ES-2	GDSC1	4.8317	6.3561	2.4948	0.5978
SNU-119	CTRP2	4.9443	6.9218	4.5275	8.8768
OVKATE	GDSC1	5.0099	6.6379	2.4622	0.595
OVCAR-5	GDSC1; CTRP2	5.0909	5.963	5.0248	6.5815
OAW42	GDSC1; CTRP2	5.7665	6.2848	5.6533	2.2732
DOV13	CTRP2	6.0225	7.9507	4.3028	1.7771
Caov-4	GDSC1	6.1072	8.4217	2.2426	0.6716
OVISE	GDSC1; CTRP2	6.1171	19.9327	-1.5258	23.5415
COV362	CTRP2	6.5307	8.6062	5.1427	2.9482
ES2	CTRP2	6.7185	7.7136	4.7249	0.0792
OVCAR-3	GDSC1	6.8429	19.963	-2.5318	21.8948
EFO-27	GDSC1; CTRP2	6.9144	9.3801	5.034	2.8321
OV56	CTRP2	7.337	8.8181	5.5294	0.6157
OVSAHO	CTRP2	7.4271	9.1215	4.4925	0.2449
JHOM-1	CTRP2	7.5233	9.4695	5.3507	1.0181
SNU-8	CTRP2	7.5943	8.8454	5.6313	0.2415
OV7	CTRP2	7.6133	9.6689	5.3123	1.0682
JHOC-5	CTRP2	7.8225	9.3696	5.5287	0.3611
TOV-21G	GDSC1; CTRP2	7.9396	9.3064	5.5986	0.2223
FU-OV-1	GDSC1; CTRP2	7.987	9.6431	5.4939	0.3677
HEY A8	CTRP2	8.0507	9.1647	5.6881	0.064
OV-90	GDSC1; CTRP2	8.1332	9.6296	5.5567	0.2064
Caov-3	GDSC1; CTRP2	8.181	9.6874	5.5542	0.198
OVK18	CTRP2	8.2112	9.6913	5.5641	0.1764
JHOS-2	CTRP2	8.2289	9.6116	5.5985	0.1283
RMG-I	GDSC1; CTRP2	8.2701	10.2045	5.3997	0.4504
OVCAR-4	GDSC1; CTRP2	8.2912	16.5984	2.5023	10.8096
EFO-21	GDSC1; CTRP2	8.3194	9.5833	5.6402	0.0727
TOV-112D	GDSC1; CTRP2	8.3913	10.3126	5.409	0.3848
TYK-nu	GDSC1; CTRP2	8.5096	10.0371	5.5526	0.1317
COV644	CTRP2	8.5682	10.2156	5.5119	0.1695
SNU-840	CTRP2	8.5764	10.2271	5.5109	0.1691
IGROV-1	GDSC1; CTRP2	8.599	10.544	5.4065	0.3202
ONCO-DG-1	CTRP2	8.6164	10.1507	5.5517	0.1155
COV434	CTRP2	8.6465	10.7495	5.3499	0.4072
OVTOKO	GDSC1; CTRP2	8.6498	10.4689	5.4529	0.2321
MCAS	CTRP2	8.7047	10.2689	5.5425	0.1117
OVCAR-8	GDSC1; CTRP2	8.8295	10.5702	5.4836	0.1546
Kuramochi	GDSC1; CTRP2	8.8767	10.6431	5.4754	0.1557
SK-OV-3	GDSC1; CTRP2	8.9071	21.0954	0.7507	15.8519
OAW28	GDSC1; CTRP2	9.0145	10.7613	5.4839	0.1249
-----------


⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	GDSC1; CTRP2	7.3321	9.7845	5.1073	2.0387
ACC-MESO-1	CTRP2	7.4655	8.5922	5.6732	0.2073
JL-1	CTRP2	8.0105	9.3664	5.6041	0.1665
NCI-H2452	GDSC1; CTRP2	8.0527	14.5253	3.3384	7.9717
NCI-H28	GDSC1; CTRP2	8.191	9.9335	5.4687	0.3414
NCI-H2052	GDSC1; CTRP2	8.2522	16.5171	2.5144	10.8235
IST-Mes1	GDSC1; CTRP2	8.6271	10.4642	5.446	0.2481
MPP 89	GDSC1; CTRP2	11.9709	27.7755	-0.3679	14.8907
-----------


⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PC-3	GDSC1	4.0618	8.0739	1.2842	9.9772
LNCaP clone FGC	GDSC1; CTRP2	4.7013	6.0017	4.59	9.336
DU145	GDSC1; CTRP2	6.3325	8.6461	4.9751	3.9682
PaCa-3	CTRP2	8.0753	9.1877	5.6889	0.0605
22Rv1	GDSC1; CTRP2	8.4947	10.3368	4.4565	0.0969
VCaP	GDSC1; CTRP2	11.6259	27.262	-0.3511	15.2701
-----------


⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC1; CTRP2	5.4653	7.0843	4.988	5.701
YD-15	CTRP2	6.4811	9.5201	3.8604	2.9909
-----------

Cancer Drug Sensitivity Data Curated from 74 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH-4	GDSC1	2.2933	5.1824	1.2755	16.3321
CHL-1	GDSC1	2.7298	3.8865	2.3154	6.4643
MZ-MEL-2	GDSC1	2.7436	4.4933	2.0302	8.6301
LB2518-MEL	GDSC1	2.8986	12.4296	-1.7996	30.0858
CP66-MEL	GDSC1	2.9081	3.9545	2.4442	4.7283
DJM-1	GDSC1	2.9472	3.9067	2.5019	4.1239
GAK	GDSC1	3.0588	5.1383	1.9794	7.8362
451Lu	GDSC1	3.0607	4.9383	2.081	7.0302
Hs 938.T	GDSC1	3.3318	6.7437	1.397	11.4006
A-431	GDSC1	3.4557	5.5521	2.0809	5.754
LB373-MEL-D	GDSC1	3.5828	5.262	2.3101	3.6572
IST-MEL1	GDSC1	3.7688	7.291	1.4566	9.5709
CP50-MEL-B	GDSC1	3.9423	11.3935	-0.4397	20.9704
A-388	GDSC1	3.9849	6.4546	2.0083	4.8857
MZ-MEL-7	GDSC1	4.1697	6.2088	2.2337	2.8953
MMAc-SF	GDSC1	4.4665	5.8513	2.5331	0.7336
VMRC-MELG	GDSC1	4.8233	6.3755	2.4841	0.6444
COLO 783	GDSC1	4.8804	6.1262	2.5968	0.2526
WM1552C	GDSC1	4.8851	9.3956	1.2035	8.4122
UACC-257	GDSC1; CTRP2	5.155	6.7575	4.8164	7.1829
COLO 679	GDSC1	5.1808	6.6954	2.5078	0.3567
G-mel	GDSC1	5.2829	33.0926	-10.1887	37.9328
WM278	GDSC1	5.3391	7.0101	2.4555	0.429
M14	GDSC1	5.3895	14.1903	-0.7505	18.3564
WM266-4	CTRP2	5.4488	5.904	5.4266	4.0438
WM115	GDSC1; CTRP2	5.5897	5.9523	5.5699	3.0972
WM35	GDSC1	5.7022	22.1636	-4.4335	29.4183
Hs 852.T	CTRP2	5.8508	7.4128	3.5655	0.4379
Hs 936.T	CTRP2	5.9388	7.6719	3.5039	0.552
HMV-II	GDSC1	6.3892	21.8008	-3.7472	26.347
RPMI-7951	GDSC1; CTRP2	6.5475	8.0888	5.405	1.8576
G-361	GDSC1; CTRP2	6.5489	16.282	-0.1001	14.3801
MeWo	GDSC1; CTRP2	6.7347	10.3082	4.4568	5.4525
COLO 741	CTRP2	6.7553	18.983	0.1576	21.2698
SK-MEL-24	GDSC1; CTRP2	7.0046	8.3751	5.5485	0.8075
Hs 688(A).T	CTRP2	7.3498	8.4567	5.6767	0.2425
SK-MEL-30	GDSC1; CTRP2	7.4198	9.6188	5.2315	1.5037
SK-MEL-2	GDSC1; CTRP2	7.5577	8.6008	5.7057	0.1279
SK-MEL-3	GDSC1; CTRP2	7.5729	9.0056	5.5619	0.3978
A101D	GDSC1; CTRP2	7.5838	8.9932	5.5714	0.371
Hs 294T	CTRP2	7.6673	8.8858	5.6454	0.1928
Hs 839.T	CTRP2	7.671	18.1027	1.3114	16.0304
IPC-298	GDSC1; CTRP2	7.6826	14.8667	2.9128	10.1846
WT2-iPS	GDSC1; CTRP2	7.7481	8.9208	5.6636	0.1431
WM88	CTRP2	7.7765	9.6147	5.4133	0.6621
IGR-1	GDSC1; CTRP2	7.7996	8.9177	5.6837	0.106
SK-MEL-1	GDSC1; CTRP2	7.8466	8.9524	5.6886	0.0921
WM1799	CTRP2	7.8611	9.1918	5.6097	0.1961
SK-MEL-5	GDSC1; CTRP2	7.8776	9.0892	5.6524	0.1299
UACC-62	GDSC1; CTRP2	7.8996	19.4201	0.8327	17.2034
HMCB	CTRP2	7.9145	8.6971	5.7966	0.0124
Hs 940.T	GDSC1; CTRP2	7.9152	9.3418	5.5764	0.2359
CJM [Human melanoma]	CTRP2	7.9215	8.964	5.711	0.0599
A2058	GDSC1; CTRP2	7.9399	8.7778	5.7787	0.0176
RVH-421	GDSC1; CTRP2	7.976	9.511	5.5385	0.2842
Hs 895.T	CTRP2	8.0483	9.3518	5.6231	0.1326
SK-MEL-31	CTRP2	8.0567	9.3282	5.6344	0.1173
K029AX	CTRP2	8.0728	11.6435	4.7	2.7318
IGR-39	CTRP2	8.1085	15.4323	2.9395	9.4325
Hs 944.T	CTRP2	8.1664	9.6721	5.5541	0.2019
Mel JuSo	GDSC1; CTRP2	8.1906	9.77	5.5282	0.236
COLO 800	GDSC1; CTRP2	8.1941	10.071	5.4185	0.4419
COLO 792	GDSC1; CTRP2	8.2229	9.5666	5.6119	0.114
A-375	GDSC1; CTRP2	8.2391	9.8626	5.5135	0.2462
LOX-IMVI	GDSC1; CTRP2	8.3533	9.7342	5.6008	0.1049
MDA-MB-435S	CTRP2	8.3702	9.5697	5.6621	0.051
HT-144	GDSC1; CTRP2	8.4186	10.3745	5.397	0.3982
COLO 829	GDSC1; CTRP2	8.4498	9.8973	5.5793	0.1125
WM793	GDSC1; CTRP2	8.5334	9.9195	5.601	0.0805
WM983B	CTRP2	8.9674	11.0446	5.3679	0.2797
Mel Ho	GDSC1; CTRP2	10.583	20.8621	1.9898	9.5426
IGR-37	GDSC1; CTRP2	12.772	34.3025	-2.9473	19.8719
SK-MEL-28	GDSC1; CTRP2	13.3456	28.1801	0.3072	11.5126
EquiPSC Line K2	GDSC1	5.3693	18.0733	-2.6648	25.6706
-----------


⏷ Show the Full List of 74 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1	2.1196	3.193	1.9803	11.9372
-----------

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
GCIY	GDSC1	3.0282	4.9979	2.0244	7.591
TMK-1	GDSC1	3.2286	4.6737	2.3452	4.3932
MKN28	GDSC1	3.4833	6.2738	1.7463	8.2489
RERF-GC-1B	GDSC1	4.2374	7.4042	1.724	6.3359
NUGC-3	GDSC1; CTRP2	4.3319	8.1278	2.2672	8.2644
SCH	GDSC1	4.3724	10.2614	0.4398	14.7311
ECC10	GDSC1; CTRP2	4.3845	5.9329	4.2621	11.4837
SNU-16	GDSC1	4.7964	6.0981	2.5752	0.3487
RF-48	GDSC1	5.1392	11.7849	0.2371	13.8518
TGBC11TKB	GDSC1	5.1671	7.1405	2.3381	0.9628
HSC-39	GDSC1	5.2559	6.9507	2.4449	0.5041
MKN1	GDSC1; CTRP2	5.4922	7.2587	4.9323	6.7726
HGC-27	GDSC1; CTRP2	5.7378	14.8988	1.3592	19.4883
Hs 746.T	CTRP2	6.2858	7.808	5.3548	2.4646
GSU	CTRP2	6.807	7.539	5.797	0.2143
SNU-668	CTRP2	6.8524	8.1107	4.6354	0.1703
MKN45	GDSC1; CTRP2	7.2934	11.0643	4.4836	4.5047
MKN7	GDSC1; CTRP2	7.6184	10.268	5.0552	1.9272
ECC12	CTRP2	7.7321	8.7442	5.7193	0.0776
SNU-5	GDSC1; CTRP2	7.8684	9.4281	5.5257	0.3489
MKN74	CTRP2	7.8728	10.6234	5.0392	1.7409
SH-10-TC	CTRP2	7.9575	9.0242	5.7032	0.0623
LMSU	CTRP2	7.964	11.8475	4.5437	3.4237
SNU-620	CTRP2	8.0229	9.2031	5.6654	0.0888
AGS	GDSC1; CTRP2	8.0561	9.8713	5.4364	0.4621
KATO III	CTRP2	8.0768	9.836	5.4584	0.4055
GSS	CTRP2	8.0815	9.3128	5.6486	0.0972
Fu97	GDSC1; CTRP2	8.0854	9.5434	5.5693	0.1995
OCUM-1	GDSC1; CTRP2	8.1065	9.8045	5.4824	0.3453
NUGC-4	GDSC1; CTRP2	8.32	10.1475	5.4413	0.3481
23132/87	GDSC1; CTRP2	8.4152	9.9907	5.5344	0.1719
SNU-601	CTRP2	8.4888	10.1434	5.5079	0.1916
SNU-216	CTRP2	8.5445	10.114	5.5386	0.1416
SNU-719	CTRP2	8.6565	10.239	5.5356	0.126
SNU-1	GDSC1; CTRP2	8.6654	18.4499	1.8669	12.5392
KE-39	CTRP2	8.8529	11.2924	5.2314	0.5672
IM95	GDSC1; CTRP2	8.8871	10.8116	5.4204	0.2229
HuG1-N	CTRP2	8.9296	21.8022	0.4215	16.8165
NCI-N87	GDSC1; CTRP2	9.19	11.2454	5.3799	0.2122
SNU-685	CTRP2	5.821	6.4046	5.6558	2.1227
SNG-M	GDSC1; CTRP2	8.3617	10.1052	5.4733	0.2776
SNU-1077	CTRP2	8.7114	10.238	5.5554	0.0986
-----------


⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IHH-4	GDSC1	2.9377	4.4465	2.2242	6.3479
ASH-3	GDSC1	2.9622	3.8231	2.5565	3.6371
KMH-2	GDSC1	3.3558	5.1455	2.2074	5.0738
HTC-C3	GDSC1	3.5946	6.8836	1.5287	9.5599
K5	GDSC1	3.9931	9.6381	0.4679	15.6944
WRO	GDSC1	5.2872	6.9955	2.4409	0.4997
ML-1 [Human leukemia]	GDSC1; CTRP2	6.6543	32.014	-6.4357	33.6217
CGTH-W-1	GDSC1; CTRP2	7.8591	9.0971	5.6427	0.1469
CAL-62	GDSC1; CTRP2	7.9132	8.9863	5.7006	0.0701
B-CPAP	GDSC1; CTRP2	8.042	9.8609	5.4344	0.4729
SW579	CTRP2	8.1155	9.307	5.6626	0.0784
FTC-238	CTRP2	8.1872	10.5756	5.2178	0.9442
FTC-133	GDSC1; CTRP2	8.2623	9.6646	5.5922	0.1297
TT	GDSC1; CTRP2	8.3356	9.7202	5.5994	0.1092
8305C	GDSC1; CTRP2	8.441	9.89	5.5786	0.1145
BHT-101	GDSC1; CTRP2	8.6728	10.1858	5.5596	0.0998
8505C	GDSC1; CTRP2	9.6404	26.5686	-1.3969	20.5909
TT2609-C02	GDSC1; CTRP2	11.9787	24.3433	1.2403	10.3091
-----------


⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LB771-HNC	GDSC1	1.1638	3.1872	0.942	24.4072
Ca9-22	GDSC1	2.9531	6.3386	1.2914	13.5356
BB30-HNC	GDSC1	3.0056	6.4362	1.2866	13.3774
YD-10B	CTRP2	3.0167	17.1381	-2.7656	32.9922
UPCI-SCC-090	GDSC1	3.0821	5.3488	1.8933	8.4303
PCI-06A	GDSC1	3.2022	12.4097	-1.5374	28.1391
BICR 10	GDSC1	3.439	6.0026	1.847	7.6111
PCI-15A	GDSC1	3.4672	13.6209	-1.9263	28.6172
KON	GDSC1	3.6359	6.7548	1.6226	8.7254
OSC-20	GDSC1	3.7794	9.8749	0.1886	18.0717
BICR 78	GDSC1	4.0936	6.4658	2.0715	4.178
SCC-15	GDSC1	4.1274	6.2287	2.2003	3.2052
PCI-04B	GDSC1	4.3612	7.7498	1.641	6.6298
HO-1-u-1	GDSC1	4.4178	6.2141	2.3642	1.6614
HO-1-N-1	GDSC1	4.6751	6.5779	2.3393	1.4613
NCI-H3118	GDSC1	4.7105	17.4021	-2.83	27.8184
JHU-011	GDSC1	4.7853	7.614	1.9561	3.5816
JHU-029	GDSC1	4.9402	9.8592	1.0211	9.4919
HSC-2	GDSC1; CTRP2	5.2064	5.9947	5.1429	5.8039
PCI-38	GDSC1	5.3291	7.2696	2.3568	0.7628
FaDu	GDSC1; CTRP2	5.4121	6.7214	5.0987	5.3921
SAS	GDSC1	5.4465	17.8119	-2.4792	24.9055
SAT [Human HNSCC]	GDSC1	5.5244	10.9626	0.8741	9.0898
OSC-19	GDSC1	5.5348	7.2708	2.4365	0.3914
BB49-HNC	GDSC1	5.5472	7.5522	2.3399	0.679
SKN-3	GDSC1	5.5762	7.2237	2.4683	0.297
DOK	GDSC1	5.5784	16.3716	-1.6778	21.7938
JHU-022	GDSC1	5.6148	7.7403	2.2976	0.784
PCI-30	GDSC1	5.6868	7.4344	2.4353	0.3334
KOSC-2	GDSC1	5.7783	12.9642	0.0994	13.0668
SCC-4	GDSC1; CTRP2	5.9577	7.1802	5.4027	2.8695
YD-8	CTRP2	6.552	9.1722	4.8807	3.9946
Detroit 562	GDSC1; CTRP2	6.7694	10.2911	3.6812	3.3551
HSC-3	GDSC1; CTRP2	6.9919	8.4378	4.5714	0.2374
CAL-27	GDSC1; CTRP2	7.2601	11.24	4.3766	4.9805
BICR 56	CTRP2	7.2833	9.3341	5.2813	1.4625
SNU-46	CTRP2	7.4034	9.3406	4.4034	0.4192
SNU-899	CTRP2	7.549	9.1032	4.5439	0.1443
BICR 6	CTRP2	7.6086	9.1018	5.5402	0.4318
PE/CA-PJ15	GDSC1; CTRP2	7.7755	9.8009	5.3375	0.8739
BICR 22	GDSC1; CTRP2	7.8033	8.9698	5.6668	0.1265
PE/CA-PJ49	CTRP2	7.9545	9.3651	5.5832	0.2129
PE/CA-PJ41 (clone D2)	CTRP2	8.0439	9.496	5.5704	0.2087
HSC-4	GDSC1; CTRP2	8.0552	9.175	5.6862	0.065
BICR 16	CTRP2	8.0558	9.7512	5.4816	0.3659
BHY	GDSC1; CTRP2	8.2215	9.7043	5.5634	0.1751
SNU-1076	CTRP2	8.269	9.3647	5.6959	0.0382
SNU-1066	CTRP2	8.3047	9.78	5.5675	0.1518
SCC-25	GDSC1; CTRP2	8.3991	10.2635	5.4302	0.3418
BICR 31	GDSC1; CTRP2	8.4667	10.4282	5.3965	0.3819
CAL-33	GDSC1; CTRP2	8.645	10.9232	5.2843	0.5407
BICR 18	CTRP2	8.933	22.4277	0.1176	17.699
SNU-1041	CTRP2	9.1037	10.6659	5.5468	0.0636
SNU-1214	CTRP2	9.2137	20.0941	1.4533	13.1419
SCC-9	GDSC1; CTRP2	9.873	16.5629	3.5292	5.0348
-----------


⏷ Show the Full List of 55 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW780	GDSC1	4.6584	6.412	2.3984	1.1765
HT-1197	GDSC1	4.9043	22.7457	-5.3342	32.8857
TCCSUP	GDSC1; CTRP2	5.3341	6.5686	5.0825	5.6634
BC-3C	CTRP2	5.7063	6.243	5.607	2.6166
RT-4	GDSC1; CTRP2	5.7179	8.9549	2.8409	3.2234
KMBC-2	CTRP2	6.0018	8.5613	4.7503	5.5223
BFTC-905	GDSC1; CTRP2	6.4881	8.019	5.398	1.9708
253J	CTRP2	6.5496	8.5919	5.1632	2.8354
639V	GDSC1; CTRP2	7.5299	16.4928	2.0006	13.8646
UM-UC-1	CTRP2	7.5594	10.277	5.0176	2.1224
CAL-29	GDSC1; CTRP2	7.5997	8.9844	5.5814	0.3416
253J-BV	CTRP2	7.7776	9.2126	5.5691	0.296
647V	GDSC1; CTRP2	7.879	9.3485	5.5596	0.278
RT-112	GDSC1; CTRP2	8.1145	9.2971	5.6656	0.0758
UM-UC-3	GDSC1; CTRP2	8.1333	9.9141	5.4524	0.3953
SCaBER	CTRP2	8.2912	9.4906	5.6616	0.0588
JMSU-1	CTRP2	8.3796	9.5588	5.669	0.0458
VM-CUB-1	CTRP2	8.5166	10.1179	5.5271	0.1606
J82	GDSC1; CTRP2	8.6477	10.3734	5.4858	0.1868
5637	GDSC1; CTRP2	8.7939	10.5227	5.4871	0.1568
SW1710	GDSC1; CTRP2	8.9225	10.7114	5.4683	0.1559
HT-1376	GDSC1; CTRP2	9.0066	11.0813	5.3696	0.2673
T24	GDSC1; CTRP2	9.1521	11.5577	5.254	0.4147
KU-19-19	GDSC1; CTRP2	13.0785	32.1112	-1.6962	16.8408
-----------


⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NT2-D1	GDSC1	2.5559	3.56	2.2984	7.384
C-33 A	GDSC1	2.7361	13.3022	-2.3726	32.3709
SiSo	GDSC1	3.0749	9.8403	-0.358	23.5148
JEG-3	GDSC1	3.1511	6.1791	1.5346	10.9752
PA-1	GDSC1	3.2039	4.8363	2.2458	5.2497
SW962	GDSC1	3.2858	9.3118	0.079	20.3911
CAL-39	GDSC1	3.3257	5.0667	2.2239	5.0372
DoTc2 4510	GDSC1	3.4176	5.8272	1.9175	7.1324
SW756	GDSC1	3.5353	8.0846	0.8889	14.393
SKN	GDSC1	3.6759	6.2211	1.912	6.4118
KGN	GDSC1	3.7592	13.0613	-1.4128	25.8535
NCC-IT	GDSC1	3.7904	6.6042	1.8066	6.8892
HEC-1	GDSC1	3.8927	6.8886	1.74	7.1069
SiHa	GDSC1	4.175	6.8436	1.9469	4.8823
OMC-1 [Human cervical carcinoma]	GDSC1	4.2073	7.7493	1.5405	7.7361
C-4-I	GDSC1	4.3208	11.1334	-0.0253	17.6099
DSH1	GDSC1	4.3915	6.8243	2.0852	3.4633
OVMIU	GDSC1	4.6435	8.5022	1.4682	7.1743
SW954	GDSC1	4.7825	7.1438	2.1574	2.3397
NEC8	GDSC1	4.8784	6.6899	2.3873	1.0052
JAR	GDSC1	5.0636	6.5515	2.5147	0.3926
LB831-BLC	GDSC1	5.1922	6.9643	2.4148	0.6444
HT-3	GDSC1	5.5219	7.3678	2.3971	0.5092
MS751	GDSC1	5.6706	7.4853	2.4114	0.3991
ME-180	GDSC1	5.9752	7.9344	2.3662	0.3893
SKG-IIIa	GDSC1	6.2908	14.6741	-0.3752	14.3831
BPH-1	GDSC1	6.3128	9.183	2.0438	1.2414
Ca Ski	GDSC1	7.3542	18.4157	-1.4514	16.9259
HeLa	GDSC1; CTRP2	7.4494	8.4078	5.7334	0.1137
-----------


⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bexarotene

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Bexarotene and Methoxsalen.	Mycosis fungoides [2B01]	[12]
-----------

Coadministration of a Drug Treating the Disease Different from Bexarotene (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[12]
Methylergonovine	DMBEX4O	Moderate	Increased metabolism of Bexarotene caused by Methylergonovine mediated induction of CYP450 enzyme.	Abortion [JA00]	[12]
Repaglinide	DM5SXUV	Moderate	Increased metabolism of Bexarotene caused by Repaglinide mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[13]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Thioguanine.	Acute myeloid leukaemia [2A60]	[14]
Ivosidenib	DM8S6T7	Minor	Increased metabolism of Bexarotene caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Bexarotene caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Oliceridine	DM6MDCF	Moderate	Increased metabolism of Bexarotene caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[17]
Mitotane	DMU1GX0	Minor	Increased metabolism of Bexarotene caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[15]
Donepezil	DMIYG7Z	Moderate	Increased metabolism of Bexarotene caused by Donepezil mediated induction of CYP450 enzyme.	Alzheimer disease [8A20]	[18]
Ivabradine	DM0L594	Moderate	Increased metabolism of Bexarotene caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[19]
Bepridil	DM0RKS4	Moderate	Increased metabolism of Bexarotene caused by Bepridil mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[19]
Dronedarone	DMA8FS5	Moderate	Increased metabolism of Bexarotene caused by Dronedarone mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[20]
Nifedipine	DMSVOZT	Moderate	Increased metabolism of Bexarotene caused by Nifedipine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[19]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[21]
Buspirone	DMBS632	Moderate	Increased metabolism of Bexarotene caused by Buspirone mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[22]
Clorazepate	DMC3JST	Moderate	Increased metabolism of Bexarotene caused by Clorazepate mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[19]
Alprazolam	DMC7XDN	Moderate	Increased metabolism of Bexarotene caused by Alprazolam mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[19]
Methylphenobarbital	DMDSWAG	Minor	Increased metabolism of Bexarotene caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[23]
Montelukast	DMD157S	Moderate	Increased metabolism of Bexarotene caused by Montelukast mediated induction of CYP450 enzyme.	Asthma [CA23]	[24]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Roflumilast.	Asthma [CA23]	[19]
Tindamax	DM3OWT4	Moderate	Increased metabolism of Bexarotene caused by Tindamax mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Telithromycin	DMZ4P3A	Moderate	Increased metabolism of Bexarotene caused by Telithromycin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Cariprazine	DMJYDVK	Moderate	Increased metabolism of Bexarotene caused by Cariprazine mediated induction of CYP450 enzyme.	Bipolar disorder [6A60]	[19]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Bexarotene and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[26]
Ixabepilone	DM2OZ3G	Moderate	Increased metabolism of Bexarotene caused by Ixabepilone mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Lapatinib	DM3BH1Y	Moderate	Increased metabolism of Bexarotene caused by Lapatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Bexarotene caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Exemestane	DM9HPW3	Moderate	Increased metabolism of Bexarotene caused by Exemestane mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Esterified estrogens	DM9KZDO	Moderate	Increased metabolism of Bexarotene caused by Esterified estrogens mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Bexarotene caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Bexarotene caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Letrozole	DMH07Y3	Moderate	Increased metabolism of Bexarotene caused by Letrozole mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Quinestrol	DMJ6H1Z	Moderate	Increased metabolism of Bexarotene caused by Quinestrol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Tamoxifen	DMLB0EZ	Moderate	Increased metabolism of Bexarotene caused by Tamoxifen mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Cabazitaxel	DMPAZHC	Moderate	Increased metabolism of Bexarotene caused by Cabazitaxel mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[33]
Toremifene	DMQYUWG	Moderate	Increased metabolism of Bexarotene caused by Toremifene mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Bosutinib	DMTI8YE	Moderate	Increased metabolism of Bexarotene caused by Bosutinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Estradiol	DMUNTE3	Moderate	Increased metabolism of Bexarotene caused by Estradiol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Atorvastatin	DMF28YC	Moderate	Increased metabolism of Bexarotene caused by Atorvastatin mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[36]
Macitentan	DMP79A1	Moderate	Increased metabolism of Bexarotene caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[37]
Secobarbital	DM14RF5	Minor	Increased metabolism of Bexarotene caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[15]
PF-04449913	DMSB068	Moderate	Increased metabolism of Bexarotene caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[38]
Phenylbutazone	DMAYL0T	Minor	Increased metabolism of Bexarotene caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[15]
Irinotecan	DMP6SC2	Moderate	Increased metabolism of Bexarotene caused by Irinotecan mediated induction of CYP450 enzyme.	Colorectal cancer [2B91]	[39]
Drospirenone	DM1A9W3	Major	Increased metabolism of Bexarotene caused by Drospirenone mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[40]
Levonorgestrel	DM1DP7T	Major	Increased metabolism of Bexarotene caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[40]
Ulipristal	DMBNI20	Moderate	Increased metabolism of Bexarotene caused by Ulipristal mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[19]
Mestranol	DMG3F94	Major	Increased metabolism of Bexarotene caused by Mestranol mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[41]
Norgestimate	DMYP4XC	Major	Increased metabolism of Bexarotene caused by Norgestimate mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[41]
Levobupivacaine	DM783CH	Minor	Increased metabolism of Bexarotene caused by Levobupivacaine mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[42]
Alfentanil	DMVO0UB	Moderate	Increased metabolism of Bexarotene caused by Alfentanil mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[43]
Nimodipine	DMQ0RKZ	Moderate	Increased metabolism of Bexarotene caused by Nimodipine mediated induction of CYP450 enzyme.	Coronary vasospastic disease [BA85]	[19]
Methadone	DMTW6IU	Moderate	Increased metabolism of Bexarotene caused by Methadone mediated induction of CYP450 enzyme.	Cough [MD12]	[17]
Osilodrostat	DMIJC9X	Moderate	Increased metabolism of Bexarotene caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[44]
Aminoglutethimide	DMWFHMZ	Minor	Increased metabolism of Bexarotene caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[15]
Ivacaftor	DMZC1HS	Moderate	Increased metabolism of Bexarotene caused by Ivacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[45]
Rivaroxaban	DMQMBZ1	Moderate	Increased metabolism of Bexarotene caused by Rivaroxaban mediated induction of CYP450 enzyme.	Deep vein thrombosis [BD71]	[46]
Vilazodone	DM4LECQ	Moderate	Increased metabolism of Bexarotene caused by Vilazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[47]
Vortioxetine	DM6F1PU	Moderate	Increased metabolism of Bexarotene caused by Vortioxetine mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Trazodone	DMK1GBJ	Moderate	Increased metabolism of Bexarotene caused by Trazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[19]
Griseofulvin	DMK54YG	Minor	Increased metabolism of Bexarotene caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[15]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Increased metabolism of Bexarotene caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme.	Discovery agent [N.A.]	[49]
Oxybutynine	DMJPBAX	Moderate	Increased metabolism of Bexarotene caused by Oxybutynine mediated induction of CYP450 enzyme.	Discovery agent [N.A.]	[19]
Oestradiol valerate and dienogest	DMZK0FQ	Major	Increased metabolism of Bexarotene caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme.	Endometriosis [GA10]	[41]
Zonisamide	DM0DTF7	Moderate	Increased metabolism of Bexarotene caused by Zonisamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[50]
Primidone	DM0WX6I	Minor	Increased metabolism of Bexarotene caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Felbamate	DM1V5ZS	Minor	Increased metabolism of Bexarotene caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Oxcarbazepine	DM5PU6O	Minor	Increased metabolism of Bexarotene caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Ethosuximide	DMDZ9LT	Moderate	Increased metabolism of Bexarotene caused by Ethosuximide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Cenobamate	DM8KLU9	Minor	Increased metabolism of Bexarotene caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Tiagabine	DMKSQG0	Moderate	Increased metabolism of Bexarotene caused by Tiagabine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Bexarotene caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Fosphenytoin	DMOX3LB	Minor	Increased metabolism of Bexarotene caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Clonazepam	DMTO13J	Moderate	Increased metabolism of Bexarotene caused by Clonazepam mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Rufinamide	DMWE60C	Minor	Increased metabolism of Bexarotene caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Bexarotene caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Carbamazepine	DMZOLBI	Minor	Increased metabolism of Bexarotene caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Eslicarbazepine	DMZREFQ	Minor	Increased metabolism of Bexarotene caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Cannabidiol.	Epileptic encephalopathy [8A62]	[19]
Nicardipine	DMCDYW7	Moderate	Increased metabolism of Bexarotene caused by Nicardipine mediated induction of CYP450 enzyme.	Essential hypertension [BA00]	[19]
Praziquantel	DMOU1PK	Moderate	Increased metabolism of Bexarotene caused by Praziquantel mediated induction of CYP450 enzyme.	Flatworm infection [1F70-1F86]	[52]
Bay 80-6946	DMLOS5R	Moderate	Increased metabolism of Bexarotene caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[53]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Bexarotene caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[54]
Solifenacin	DMG592Q	Moderate	Increased metabolism of Bexarotene caused by Solifenacin mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[55]
Mirabegron	DMS1GYT	Minor	Increased metabolism of Bexarotene caused by Mirabegron mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[56]
Caspofungin	DMGQIPT	Moderate	Increased metabolism of Bexarotene caused by Caspofungin mediated induction of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[57]
Cisapride	DMY7PED	Moderate	Increased metabolism of Bexarotene caused by Cisapride mediated induction of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[19]
Ripretinib	DM958QB	Moderate	Increased metabolism of Bexarotene caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[12]
Avapritinib	DMK2GZX	Moderate	Increased metabolism of Bexarotene caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[19]
Sulfinpyrazone	DMEV954	Minor	Increased metabolism of Bexarotene caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[15]
Ergotamine	DMKR3C5	Moderate	Increased metabolism of Bexarotene caused by Ergotamine mediated induction of CYP450 enzyme.	Headache [8A80-8A84]	[12]
Boceprevir	DMBSHMF	Moderate	Increased metabolism of Bexarotene caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[58]
Telaprevir	DMMRV29	Moderate	Increased metabolism of Bexarotene caused by Telaprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[58]
Rifampin	DMA8J1G	Minor	Increased metabolism of Bexarotene caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[23]
Rifapentine	DMCHV4I	Minor	Increased metabolism of Bexarotene caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[15]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[59]
MK-1439	DM215WE	Moderate	Increased metabolism of Bexarotene caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Delavirdine	DM3NF5G	Moderate	Increased metabolism of Bexarotene caused by Delavirdine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Fosamprenavir	DM4W9B3	Moderate	Increased metabolism of Bexarotene caused by Fosamprenavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Fostemsavir	DM50ILT	Minor	Increased metabolism of Bexarotene caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Tipranavir	DM8HJX6	Moderate	Increased metabolism of Bexarotene caused by Tipranavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Bexarotene caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Dolutegravir	DMCZGRE	Minor	Increased metabolism of Bexarotene caused by Dolutegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Saquinavir	DMG814N	Moderate	Increased metabolism of Bexarotene caused by Saquinavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Etravirine	DMGV8QU	Minor	Increased metabolism of Bexarotene caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Rilpivirine	DMJ0QOW	Moderate	Increased metabolism of Bexarotene caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Amprenavir	DMLMXE0	Moderate	Increased metabolism of Bexarotene caused by Amprenavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Darunavir	DMN3GCH	Moderate	Increased metabolism of Bexarotene caused by Darunavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Atazanavir	DMSYRBX	Moderate	Increased metabolism of Bexarotene caused by Atazanavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Maraviroc	DMTL94F	Moderate	Increased metabolism of Bexarotene caused by Maraviroc mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Simvastatin	DM30SGU	Moderate	Increased metabolism of Bexarotene caused by Simvastatin mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[19]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Bexarotene and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[66]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Bexarotene and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[67]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Bexarotene and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[68]
Nisoldipine	DM7ISKJ	Moderate	Increased metabolism of Bexarotene caused by Nisoldipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Levamlodipine	DM92S6N	Moderate	Increased metabolism of Bexarotene caused by Levamlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Diltiazem	DMAI7ZV	Moderate	Increased metabolism of Bexarotene caused by Diltiazem mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[69]
Amlodipine	DMBDAZV	Moderate	Increased metabolism of Bexarotene caused by Amlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Felodipine	DMOSW35	Moderate	Increased metabolism of Bexarotene caused by Felodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Tolvaptan	DMIWFRL	Moderate	Increased metabolism of Bexarotene caused by Tolvaptan mediated induction of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[19]
Fludrocortisone	DMUDIR8	Moderate	Increased metabolism of Bexarotene caused by Fludrocortisone mediated induction of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[19]
Suvorexant	DM0E6S3	Moderate	Increased metabolism of Bexarotene caused by Suvorexant mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[70]
Amobarbital	DM0GQ8N	Minor	Increased metabolism of Bexarotene caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
Ramelteon	DM7IW9J	Moderate	Increased metabolism of Bexarotene caused by Ramelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[71]
Eszopiclone	DM8RZ9H	Moderate	Increased metabolism of Bexarotene caused by Eszopiclone mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[72]
Triazolam	DMETYK5	Moderate	Increased metabolism of Bexarotene caused by Triazolam mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[19]
Pentobarbital	DMFNH7L	Minor	Increased metabolism of Bexarotene caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
Zaleplon	DMGFWSM	Minor	Increased metabolism of Bexarotene caused by Zaleplon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[73]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Bexarotene caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[74]
ITI-007	DMUQ1DO	Major	Increased metabolism of Bexarotene caused by ITI-007 mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[75]
Zolpidem	DMWOSKJ	Moderate	Increased metabolism of Bexarotene caused by Zolpidem mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[19]
Estazolam	DMZGXUM	Moderate	Increased metabolism of Bexarotene caused by Estazolam mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[19]
Naloxegol	DML0B41	Moderate	Increased metabolism of Bexarotene caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[76]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Methotrexate.	Leukaemia [2A60-2B33]	[19]
Pemigatinib	DM819JF	Moderate	Increased metabolism of Bexarotene caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[19]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Denosumab.	Low bone mass disorder [FB83]	[77]
Crizotinib	DM4F29C	Moderate	Increased metabolism of Bexarotene caused by Crizotinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[78]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Bexarotene and Porfimer Sodium.	Lung cancer [2C25]	[79]
Erlotinib	DMCMBHA	Moderate	Increased metabolism of Bexarotene caused by Erlotinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[80]
Lurbinectedin	DMEFRTZ	Moderate	Increased metabolism of Bexarotene caused by Lurbinectedin mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[81]
PF-06463922	DMKM7EW	Minor	Increased metabolism of Bexarotene caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Bexarotene caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[82]
Capmatinib	DMYCXKL	Moderate	Increased metabolism of Bexarotene caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[83]
Selpercatinib	DMZR15V	Moderate	Increased metabolism of Bexarotene caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
Halofantrine	DMOMK1V	Moderate	Increased metabolism of Bexarotene caused by Halofantrine mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[19]
Quinine	DMSWYF5	Moderate	Increased metabolism of Bexarotene caused by Quinine mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[19]
Mefloquine	DMWT905	Moderate	Increased metabolism of Bexarotene caused by Mefloquine mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[84]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Idelalisib.	Mature B-cell leukaemia [2A82]	[85]
GDC-0199	DMH0QKA	Moderate	Increased metabolism of Bexarotene caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[86]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Bexarotene caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[87]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Clofarabine.	Mature B-cell lymphoma [2A85]	[88]
Ibrutinib	DMHZCPO	Moderate	Increased metabolism of Bexarotene caused by Ibrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[89]
Vincristine	DMINOX3	Moderate	Increased metabolism of Bexarotene caused by Vincristine mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[19]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Bexarotene caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[90]
Selumetinib	DMC7W6R	Moderate	Increased metabolism of Bexarotene caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[91]
LGX818	DMNQXV8	Moderate	Increased metabolism of Bexarotene caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[92]
Dabrafenib	DMX6OE3	Minor	Increased metabolism of Bexarotene caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
Estrone	DM5T6US	Moderate	Increased metabolism of Bexarotene caused by Estrone mediated induction of CYP450 enzyme.	Menopausal disorder [GA30]	[30]
Ethinyl estradiol	DMODJ40	Major	Increased metabolism of Bexarotene caused by Ethinyl estradiol mediated induction of CYP450 enzyme.	Menopausal disorder [GA30]	[41]
Nitisinone	DMVS9WQ	Moderate	Increased metabolism of Bexarotene caused by Nitisinone mediated induction of CYP450 enzyme.	Metabolism inborn error [5C50]	[19]
Dihydroergotamine	DM5IKUF	Moderate	Increased metabolism of Bexarotene caused by Dihydroergotamine mediated induction of CYP450 enzyme.	Migraine [8A80]	[12]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Bexarotene caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[93]
Exjade	DMHPRWG	Minor	Increased metabolism of Bexarotene caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[15]
Flibanserin	DM70DTN	Moderate	Increased metabolism of Bexarotene caused by Flibanserin mediated induction of CYP450 enzyme.	Mood disorder [6A60-6E23]	[94]
Midazolam	DMXOELT	Moderate	Increased metabolism of Bexarotene caused by Midazolam mediated induction of CYP450 enzyme.	Mood/affect symptom [MB24]	[19]
Panobinostat	DM58WKG	Moderate	Increased metabolism of Bexarotene caused by Panobinostat mediated induction of CYP450 enzyme.	Multiple myeloma [2A83]	[95]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Tecfidera.	Multiple sclerosis [8A40]	[96]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Bexarotene and Siponimod.	Multiple sclerosis [8A40]	[12]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Bexarotene and Fingolimod.	Multiple sclerosis [8A40]	[97]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Ocrelizumab.	Multiple sclerosis [8A40]	[98]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Bexarotene and Ozanimod.	Multiple sclerosis [8A40]	[19]
Rifabutin	DM1YBHK	Minor	Increased metabolism of Bexarotene caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[15]
Fedratinib	DM4ZBK6	Moderate	Increased metabolism of Bexarotene caused by Fedratinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[19]
Ruxolitinib	DM7Q98D	Moderate	Increased metabolism of Bexarotene caused by Ruxolitinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[99]
Dasatinib	DMJV2EK	Moderate	Increased metabolism of Bexarotene caused by Dasatinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[100]
Modafinil	DMYILBE	Moderate	Increased metabolism of Bexarotene caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[101]
Rolapitant	DM8XP26	Moderate	Increased metabolism of Bexarotene caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[102]
Granisetron	DMIUW25	Moderate	Increased metabolism of Bexarotene caused by Granisetron mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[19]
E-2007	DMJDYNQ	Moderate	Increased metabolism of Bexarotene caused by E-2007 mediated induction of CYP450 enzyme.	Neuropathy [8C0Z]	[19]
Entrectinib	DMMPTLH	Moderate	Increased metabolism of Bexarotene caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[103]
Levomethadyl Acetate	DM06HG5	Major	Increased metabolism of Bexarotene caused by Levomethadyl Acetate mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[104]
S-297995	DM26IH8	Moderate	Increased metabolism of Bexarotene caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[19]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Bexarotene caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[105]
Butorphanol	DM5KYPJ	Moderate	Increased metabolism of Bexarotene caused by Butorphanol mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[17]
Buprenorphine	DMPRI8G	Moderate	Increased metabolism of Bexarotene caused by Buprenorphine mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[106]
Hydrocodone	DMQ2JO5	Moderate	Increased metabolism of Bexarotene caused by Hydrocodone mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[17]
Oxycodone	DMXLKHV	Moderate	Increased metabolism of Bexarotene caused by Oxycodone mediated induction of CYP450 enzyme.	Pain [MG30-MG3Z]	[17]
Albendazole	DMYZ57N	Moderate	Increased metabolism of Bexarotene caused by Albendazole mediated induction of CYP450 enzyme.	Parasitic worm infestation [1F90]	[19]
Pimavanserin	DMR7IVC	Moderate	Increased metabolism of Bexarotene caused by Pimavanserin mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[107]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Bexarotene caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[108]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Bexarotene caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[109]
Lefamulin	DME6G97	Moderate	Increased metabolism of Bexarotene caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[110]
Prednisone	DM2HG4X	Moderate	Increased metabolism of Bexarotene caused by Prednisone mediated induction of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[19]
Betamethasone	DMAHJEF	Moderate	Increased metabolism of Bexarotene caused by Betamethasone mediated induction of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[19]
Hydrocortisone	DMGEMB7	Moderate	Increased metabolism of Bexarotene caused by Hydrocortisone mediated induction of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[19]
Ergonovine	DM0VEC1	Moderate	Increased metabolism of Bexarotene caused by Ergonovine mediated induction of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[12]
Lonafarnib	DMGM2Z6	Moderate	Increased metabolism of Bexarotene caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[111]
Progesterone	DMUY35B	Moderate	Increased metabolism of Bexarotene caused by Progesterone mediated induction of CYP450 enzyme.	Preterm labour/delivery [JB00]	[30]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Bexarotene caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[112]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Bexarotene caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[113]
Silodosin	DMJSBT6	Moderate	Increased metabolism of Bexarotene caused by Silodosin mediated induction of CYP450 enzyme.	Prostate hyperplasia [GA90]	[12]
Dutasteride	DMQ4TJK	Moderate	Increased metabolism of Bexarotene caused by Dutasteride mediated induction of CYP450 enzyme.	Prostate hyperplasia [GA90]	[19]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Bexarotene and Verteporfin.	Psoriasis [EA90]	[19]
Apremilast	DMTWS9E	Moderate	Increased metabolism of Bexarotene caused by Apremilast mediated induction of CYP450 enzyme.	Psoriasis [EA90]	[114]
Bosentan	DMIOGBU	Minor	Increased metabolism of Bexarotene caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[15]
Riociguat	DMXBLMP	Moderate	Increased metabolism of Bexarotene caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[115]
Everolimus	DM8X2EH	Moderate	Increased metabolism of Bexarotene caused by Everolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[12]
Axitinib	DMGVH6N	Moderate	Increased metabolism of Bexarotene caused by Axitinib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[116]
Temsirolimus	DMS104F	Moderate	Increased metabolism of Bexarotene caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[12]
Sorafenib	DMS8IFC	Moderate	Increased metabolism of Bexarotene caused by Sorafenib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[117]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Canakinumab.	Rheumatoid arthritis [FA20]	[118]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Rilonacept.	Rheumatoid arthritis [FA20]	[118]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Bexarotene and Golimumab.	Rheumatoid arthritis [FA20]	[119]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Bexarotene caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[19]
Nafcillin	DMN9RPO	Minor	Increased metabolism of Bexarotene caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Bexarotene and Leflunomide.	Rheumatoid arthritis [FA20]	[67]
Aripiprazole	DM3NUMH	Moderate	Increased metabolism of Bexarotene caused by Aripiprazole mediated induction of CYP450 enzyme.	Schizophrenia [6A20]	[120]
Fentanyl	DM8WAHT	Moderate	Increased metabolism of Bexarotene caused by Fentanyl mediated induction of CYP450 enzyme.	Sensation disturbance [MB40]	[17]
Sufentanil	DMU7YEL	Moderate	Increased metabolism of Bexarotene caused by Sufentanil mediated induction of CYP450 enzyme.	Sensation disturbance [MB40]	[19]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Bexarotene when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[121]
Avanafil	DM75CXN	Moderate	Increased metabolism of Bexarotene caused by Avanafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[122]
Tadalafil	DMJZHT1	Moderate	Increased metabolism of Bexarotene caused by Tadalafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[19]
LDE225	DMM9F25	Moderate	Increased metabolism of Bexarotene caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[123]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Bexarotene caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[19]
Gefitinib	DM15F0X	Moderate	Increased metabolism of Bexarotene caused by Gefitinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[80]
Larotrectinib	DM26CQR	Moderate	Increased metabolism of Bexarotene caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Methylprednisolone	DM4BDON	Moderate	Increased metabolism of Bexarotene caused by Methylprednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Vinblastine	DM5TVS3	Moderate	Increased metabolism of Bexarotene caused by Vinblastine mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Docetaxel	DMDI269	Moderate	Increased metabolism of Bexarotene caused by Docetaxel mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[19]
Armodafinil	DMGB035	Moderate	Increased metabolism of Bexarotene caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[101]
LEE011	DMMX75K	Moderate	Increased metabolism of Bexarotene caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Etoposide	DMNH3PG	Moderate	Increased metabolism of Bexarotene caused by Etoposide mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[12]
Prednisolone	DMQ8FR2	Moderate	Increased metabolism of Bexarotene caused by Prednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Norethindrone	DMTY169	Major	Increased metabolism of Bexarotene caused by Norethindrone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[41]
Taxol	DMUOT9V	Moderate	Increased metabolism of Bexarotene caused by Taxol mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[124]
Doxorubicin	DMVP5YE	Moderate	Increased metabolism of Bexarotene caused by Doxorubicin mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Vinorelbine	DMVXFYE	Moderate	Increased metabolism of Bexarotene caused by Vinorelbine mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Bexarotene and Naltrexone.	Substance abuse [6C40]	[125]
Fostamatinib	DM6AUHV	Moderate	Increased metabolism of Bexarotene caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[126]
Apixaban	DM89JLN	Moderate	Increased metabolism of Bexarotene caused by Apixaban mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[127]
Brilinta	DMBR01X	Moderate	Increased metabolism of Bexarotene caused by Brilinta mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[64]
Cabozantinib	DMIYDT4	Moderate	Increased metabolism of Bexarotene caused by Cabozantinib mediated induction of CYP450 enzyme.	Thyroid cancer [2D10]	[128]
Sirolimus	DMGW1ID	Moderate	Increased metabolism of Bexarotene caused by Sirolimus mediated induction of CYP450 enzyme.	Transplant rejection [NE84]	[12]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Bexarotene and Azathioprine.	Transplant rejection [NE84]	[12]
Tacrolimus	DMZ7XNQ	Moderate	Increased metabolism of Bexarotene caused by Tacrolimus mediated induction of CYP450 enzyme.	Transplant rejection [NE84]	[12]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Bexarotene caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[129]
Astemizole	DM2HN6Q	Moderate	Increased metabolism of Bexarotene caused by Astemizole mediated induction of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[19]
Triamcinolone	DM98IXF	Moderate	Increased metabolism of Bexarotene caused by Triamcinolone mediated induction of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[19]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Bexarotene and Ganciclovir.	Virus infection [1A24-1D9Z]	[12]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Bexarotene and Valganciclovir.	Virus infection [1A24-1D9Z]	[12]
-----------


⏷ Show the Full List of 253 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bexarotene 75 mg capsule	75 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2807).
2	Bexarotene FDA Label
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8	Tributyltin and triphenyltin induce 11-hydroxysteroid dehydrogenase 2 expression and activity through activation of retinoid X receptor . Toxicol Lett. 2020 Apr 1;322:39-49. doi: 10.1016/j.toxlet.2020.01.001. Epub 2020 Jan 9.
9	Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
10	Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol. 1996 Jul;16(7):3350-60. doi: 10.1128/MCB.16.7.3350.
11	Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
12	Cerner Multum, Inc. "Australian Product Information.".
13	Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
14	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
15	Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
16	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
17	Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
18	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
19	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
21	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22	Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
23	Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
24	Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
25	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
26	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
27	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
28	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
29	Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
30	Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
31	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
32	Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
33	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
34	Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
35	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36	Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
37	Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
38	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39	Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
40	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
41	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
42	Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
43	Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
44	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
45	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
46	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
47	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
48	Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
49	Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
50	Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
51	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
52	Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
53	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
54	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
55	Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
56	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
57	Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
58	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
59	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
60	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
61	Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
62	Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
63	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
64	Canadian Pharmacists Association.
65	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
66	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
67	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
68	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
69	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
70	Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
71	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
72	Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
73	Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
74	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
75	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
76	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
78	Cerner Multum, Inc. "Canadian Product Information.".
79	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
80	Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
81	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
82	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
83	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
84	Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
85	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
86	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
87	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
88	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
89	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
90	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
91	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
92	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
93	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
94	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
95	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
96	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
97	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
98	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
99	Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
100	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
101	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
102	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
103	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
104	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
105	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
106	Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
107	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
108	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
109	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
110	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
111	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
112	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
113	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
114	Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
115	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
116	Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
117	Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
118	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
119	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
120	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
121	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
122	Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
123	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
124	Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
125	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
126	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
127	Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
128	Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
129	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.